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Cardiovascular disease is the leading cause of death in the United States, and over 20 
million people in this country currently have diabetes.  We have developed new analytical 
methods that have the potential to improve the monitoring and detection of these diseases.  Our 
work enables point-of-care sensing for biochemical markers of these diseases, advancing the 
non-invasive monitoring of diabetes and the rapid detection of myocardial ischemia.   
Close monitoring of blood glucose concentration is critical in the management of 
diabetes.  A recent approach to non-invasive monitoring is to measure glucose concentration in 
tear fluid.  However, the relationship between tear and blood glucose concentration is poorly 
understood.  We have developed an analytical method for determining tear glucose 
concentration, and have used it to help better define the correlation between tear and blood 
glucose in both fasting and non-fasting human subjects.  We also reviewed the tear glucose 
literature from the last 80 years, and have used our method to help explain some of the 
discrepancies reported.  This work will aid in developing contact lens-based sensors for tear 
glucose, and may help to decrease or eliminate finger-stick testing. 
The definitive detection of myocardial ischemia is difficult.  While some patients are sent 
home with an undetected heart attack, many are unnecessarily admitted to the hospital, costing 
the medical system ~$12 billion a year.  The Cobalt Binding Assay is a test that has shown 
promise in ruling out myocardial ischemia.  However it is limited by the need to access a central 
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clinical chemistry laboratory.  We have developed a Polymerized Crystalline Colloidal Array 
(PCCA) sensor that could be used at the bedside to rapidly detect myocardial ischemia.  This 
sensor uses photonic crystal and hydrogel technology to actuate a color change in response to 
metal cation binding affinity changes indicative of ischemia.  Specifically, the sensors monitor a 
decrease in the binding affinity of human plasma for metals such as Ni2+ and Co2+, which has 
been shown to correlate with recent ischemia.  We have also developed improved methods for 
fabricating and testing the PCCA sensors that are applicable to implementing point-of-care 
sensors for a wide variety of analytes. 
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1.0  INTRODUCTION 
1.1 POINT-OF-CARE SENSING WITH POLYMERIZED CRYSTALLINE 
COLLOIDAL ARRAYS 
Cardiovascular disease is the leading cause of death in the United States, and over 20 million 
people in this country currently have diabetes.  We have developed new analytical methods that 
have the potential to improve the monitoring and detection of these diseases.  Our work enables 
point-of-care sensing for biochemical markers of these diseases, advancing the non-invasive 
monitoring of diabetes and the rapid detection of myocardial ischemia.  A common thread in 
these studies is the development of Polymerized Crystalline Colloidal Arrays (PCCA) sensors for 
point-of-care sensing applications.   
 PCCA sensors are comprised of a hydrogel matrix that contains a ordered array of 
monodisperse colloidal nanoparticles.1  In aqueous solutions with low ionic strength, a 
Crystalline Colloidal Array (CCA) forms when highly charged polystyrene spheres self-assemble 
into a body centered cubic or face centered cubic lattice.2  Particle diameter and concentration 
can be selected so that the CCA Bragg-diffracts light in the visible range.  A PCCA is formed 
when a hydrogel, such as polyacrylamide, is polymerized around the CCA.  Swelling or 
shrinking of the hydrogel causes the lattice plane spacing to change, and the wavelength of 
diffracted light is a function of hydrogel volume.  PCCA sensors are made by modifying the 
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hydrogel so that a volume change occurs in response to a specific analyte.  In the high ionic 
strength of most biological fluids, a straightforward way to actuate a change in hydrogel volume 
is to cause crosslinks in the hydrogel to form or break.  The fabrication of PCCA sensors is 
discussed in greater detail in Chapters 5 and 6. 
 A wide variety of PCCA sensors for clinically relevant analytes have been demonstrated 
including ammonia,3 creatinine,4 lead,5 and glucose.6  One of the promising point-of-care 
applications for PCCA sensors has been for the non-invasive monitoring of glucose in the tear 
fluid.  PCCA sensors for glucose could easily be incorporated into a contact lens.7  The contact 
lens could be worn by diabetic patients, who could simply look in a mirror to determine their 
blood glucose levels.  The success of this approach depends on the relationship between tear and 
blood glucose concentrations.  This relationship, however, is poorly defined, and there are 
several contradictory reports of tear glucose concentration in the literature.   
 We undertook several studies of the glucose concentration in tears in order to help define 
the basal tear glucose concentration, determine the relationship between blood and tear glucose 
concentrations, and advance the use of PCCA glucose sensors for the non-invasive monitoring of 
diabetes.  The first study (Chapter 2) describes the development of an electrospray mass 
spectrometry method to measure low concentrations of glucose (<100 μM) in small volumes 
(~1μL).  The second study (Chapter 3) describes the use of this method in a clinical study that 
measured tear glucose in fasting, non-diabetic subjects.  Additional studies of healthy and 
diabetic subjects undergoing glucose tolerance tests were then combined with a broad review of 
the tear glucose literature to present an overview of the current understanding of tear glucose 
regulation (Chapter 4). 
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 We also present the development of a new application for PCCA sensing (Chapter 5), 
which is the rapid detection of myocardial ischemia.  The rapid and definitive detection of 
myocardial ischemia is difficult; while some patients are sent home with an undetected heart 
attack, many are unnecessarily admitted to the hospital.  The Cobalt Binding Assay is a clinical 
chemistry test that detects a change in the binding affinity of human serum for cobalt.  A 
decreased binding affinity of human serum for cobalt has been shown to correlate with recent 
myocardial ischemia in several clinical studies.  While this assay was developed to monitor a 
change in cobalt binding, the ischemia-linked change in metal binding affinity appears to be 
general for other divalent transition metal cations, including Ni2+ and Cu2+.  The precise 
mechanisms responsible for a change in the metal binding affinity of human serum after 
ischemia have not been fully explained, but apparently relate to a change in the redox potential 
of the blood. 
 The Asher group has previously demonstrated PCCA sensors for metal cations such as 
Co2+, Ni2+, and Cu2+ in acidic solutions.8  We have developed these PCCA sensors for the 
detection of Ni2+ in the presence of human plasma.  This enables the rapid detection of changes 
in the affinity of human serum for Ni2+.  While the Cobalt Binding Assay requires access to a 
central clinical chemistry laboratory and involves intensive sample processing, our PCCA 
sensors could be used in a point of care setting to rapidly detect myocardial ischemia.   
 The development of these PCCA sensors for the measurement of Ni2+ in human plasma 
also led to general improvements of PCCA fabrication methods.  One of the challenges of using 
PCCA sensors is that they must be immobilized against a flat surface to insure that diffraction is 
monitored along the normal direction.  We report on the development of methods to fabricate 
uniform PCCA sensors that are attached to a gel support film (Chapter 6).  Once attached to a 
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support film, it is much easier to manipulate the sensors and to immobilize them for sensing 
experiments.  
1.2 TEAR GLUCOSE ANALYSIS 
Development of an electrospray ionization mass spectrometry method for the analysis of tear 
glucose concentration was done in collaboration with Christopher Taormina and reported in the 
Journal of the American Society for Mass Spectrometry.9  My contributions were collecting the 
tear samples and helping to optimize and refine the analysis method. 
 Briefly, we developed a mass spectrometry-based method for the accurate determination 
of glucose concentration in tear fluid.  We use 1μL capillaries to collect tear fluid from the tear 
fluid meniscus of human subjects.  This collection method was specifically chosen to avoid 
irritation of the eye and the stimulation of reflex tearing.  We used liquid-chromatography 
electrospray ionization mass spectrometry with D-glucose-6,6-d2 as an internal standard.  
Repeated measurement of a pooled tear sample induced by onion vapors showed that the 
measurement of tear glucose with this method is precise (4% relative standard deviation).  A 
recovery experiment showed complete recovery of added glucose (94-111% recovery range).  
The tear glucose concentration in a fasting, non-diabetic subject ranged between 13 and 51 
μmol/L and the tear glucose concentration in onion-stimulated tear from a different non-diabetic 
subject ranged between 211 and 256 μmol/L.   
4 
1.3 CLINICAL STUDY OF FASTING, NON-DIABETIC SUBJECTS 
We reported a clinical study of basal tear glucose concentration in fasting, non-diabetic subjects 
using the electrospray ionization mass spectrometry method in Clinical Chemistry.10  This study 
was undertaken to help understand the discrepancies in tear glucose concentrations reported in 
the literature.  We collected three 1μL tear samples from both eyes of 25 fasting volunteers.  
Eleven of the subjects wore contact lenses during tear sampling.  We measured a median tear 
glucose concentration of 28 μmol/L with a range of 7-161 μmol/L.  We found no significant 
difference between subject who wore contact lenses and those who did not, and observed a 
significant correlation between tear and blood glucose concentrations.  We also found that the 
standard deviation of tear glucose concentration increases linearly with the average tear glucose 
concentration for individual subjects.  The tear glucose concentrations we measured were some 
of the lowest ever reported in the literature, most likely because our sampling methods avoided 
conjunctival irritation and tear stimulation. 
1.4 REVIEW OF TEAR GLUCOSE SENSING LITERATURE 
In order to make sense of the discrepancies in the tear glucose literature, we prepared an 
extensive review of tear glucose physiology and analysis.  This review covers the present 
understanding of the physiology of glucose transport in tears, the regulation of the aqueous tear 
fraction, and studies of tear glucose concentration over the last 80 years. The various tear 
collection methods employed greatly influence the measured tear glucose concentrations.  
Studies that involve mechanical irritation of the conjunctiva during sampling measure the highest 
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tear glucose concentrations, while studies that avoid tear stimulation measure the lowest 
concentrations.  This review also covers attempts to monitor tear glucose concentration in situ by 
using contact lens-based sensing devices.  We also present new observations of tear glucose 
concentration using our tear collection method purposely designed to avoid tear stimulation.  
These studies indicate the importance of the sampling method in determining tear glucose 
concentrations.  On the basis of these results, we discuss the future of in vivo tear glucose 
sensing, and outline the studies needed to resolve the remaining questions about the relationship 
between tear and blood glucose concentrations.  
1.5 MYOCARDIAL ISCHEMIA 
 
 We developed PCCA sensors Ni2+ in order to monitor changes in the affinity of human 
plasma for Ni2+ and enable the rapid, point-of-care detection of myocardial ischemia.  We 
submitted this work for peer review to Clinica Chimica Acta.  We fabricated PCCA sensors for 
Ni2+ using 5-amino-8-hydroxyquinoline as a binding agent.  Sensors were tested in aqueous 
solutions and in diluted human plasma.  Peak diffracted wavelength of the sensors was 
monitored by reflectance spectrometry and correlated with Ni2+ concentration.  The PCCA 
sensors showed a linear response to aqueous Ni2+ concentrations between 0.2 and 1.0 mmol/L, 
and can detect changes in Ni2+ concentration as small as 150 μmol/L.  The sensors respond at 
physiological pH and can be reversibly dehydrated.  The sensors detected a decrease in free Ni2+ 
of 1.0 mmol per L of plasma added.  These sensors could be used to detect a decrease in the Ni2+ 
affinity of plasma proteins which may indicate recent myocardial ischemia   
6 
1.6 FABRICATION OF UNIFORM PCCA SENSORS 
We have also developed improved methods for fabricating and testing the PCCA sensors 
that are applicable to implementing point-of-care sensors for a wide variety of analytes.  We 
found that degassing the colloidal suspension before polymerization aids in the attachment of 
PCCA sensors to gel support films.  When one side of a polymerization cell is exposed to the 
atmosphere during photopolymerization, a rainbow-colored PCCA results.  Uniform PCCA 
sensors attached to gel support films can be fabricated by carefully excluding oxygen from the 
polymerization cell. 
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2.0  ANALYSIS OF TEAR GLUCOSE CONCENTRATION WITH ELECTROSPRAY 
IONIZATION MASS SPECTROMETRY 
Taormina CR, Baca JT, Finegold DN, Asher SA, Grabowski JJ. J Am Soc Mass Spectrom 
2007;18:332–6. 
2.1 INTRODUCTION 
In the United States, 9.6% of the population over 20 years of age and 20.9% of the population 
over 60 years of age have Diabetes Mellitus.1  The Diabetes Control and Complications Trial has 
shown that close monitoring and tight control of blood glucose concentration is critical in 
preventing the complications of Diabetes.2  Current self-monitoring methods rely on invasive 
finger sticks to directly measure blood glucose levels to provide the critical information required 
to achieve glycemic control.  A number of non-invasive approaches to monitoring blood glucose 
concentrations are being pursued; however, none have been successfully developed to the point 
where they have gained widespread clinical acceptance.3  There has been significant recent 
activity in exploring non-invasive monitoring by using tear fluid glucose as an indicator for 
blood glucose.4-6  Such an approach will be effective only if the glucose concentrations in tear 
fluid are a reliable surrogate for blood glucose concentrations.   
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A survey of the literature over the last 70 years on tear glucose determinations indicates 
significant disagreement in measured tear glucose concentrations and on the relationship of tear 
fluid glucose to blood glucose concentrations.  Daum and Hill7 noted in their 1982 review of the 
human tear glucose literature that reported values of tear glucose in normal individuals range 
between 0 and 3600 μM with the median values between 110 and 280 μM.  More recently, a 
study of six non-diabetic adults found glucose concentrations in tear fluid ranging between 128 
and 166 μM with an average of 139 μM.8   
The differences in tear glucose concentrations between these reports are likely due to the 
use of different tear fluid collection methods.  Van Haeringen and Glasius specifically addressed 
the dependence of tear fluid glucose on the method of collection.9  They used a glucose 
dehydrogenase method to analyze chemically stimulated tears collected with a capillary and 
mechanically stimulated tear fluid collected by filter paper.  Van Haeringen and Glasius found 
higher glucose concentrations in the tear fluid collected by the filter paper and concluded that the 
increase is due to the mechanical stimulation of the corneal and conjunctival epithelium.9  Other 
studies reported similar findings in experiments on rabbits10 and in subjects that were tested 
immediately after swimming.7  Therefore, it is apparent that to determine a physiologically-
relevant, baseline tear glucose concentration, tear fluid must be acquired with minimal tear 
stimulation and eye irritation.     
Several previous studies used mass spectrometry to analyze tears for constituents other 
than glucose.  Fung et al.11 characterized the protein profile in the human tear fluid with 
MALDI-ToF and electrospray ionization mass spectrometry.  Ham et al.12 identified the lipid 
profile in tear fluid and reported on their variations between normal and dry eyes.  There have 
been many reports of glucose measurement by mass spectrometry on bodily fluids other than 
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tears.  The majority of these studies use gas chromatography and an electron ionization source.13-
16  With gas chromatography, glucose typically needs to be derivatized to make it more volatile.  
Other studies used liquid chromatography to bypass the volatility issue.17,18  Sodium,19 
lithium,20,21 cesium,17 and chloride22 ions have been used with electrospray ionization to form the 
cationic adduct of glucose from aqueous solutions.   
We discuss here a new, robust method of determining physiological tear glucose 
concentrations by using electrospray ionization mass spectrometry (ESI-MS). This method 
enables reliable studies of tear glucose concentrations in tear fluid.  We use a tear fluid sampling 
method that is minimally irritating to the eye to collect 1μL tear samples.  We validate the ESI-
MS method by using glucose standard solutions, artificial tear fluid, and large volumes of 
stimulated tears.  We determine tear glucose concentration in a non-diabetic, fasting adult. 
2.2 EXPERIMENTAL 
All tear samples were collected and transferred with 1 μL “Microcaps” micro-capillaries 
(Drummond Scientific Company, Broomall, USA).  The tear film meniscus on the bottom eyelid 
was visualized using a slit lamp ophthalmic microscope (American Optics, Burlington, Canada).  
The micro capillary was gently touched to this tear fluid meniscus and the tear fluid was drawn 
in by capillary action.  During half the collections, there was inadequate tear fluid to immediately 
fill the capillary with one touch.  In these cases, the subject was asked to blink in order to 
redistribute the tear fluid and the capillary was again touched to the meniscus.  This process was 
repeated until the capillary was completely filled.  A few samples required as many as five 
repetitions of this process.  Care was taken throughout tear fluid collection to avoid stimulation 
11 
of reflex tearing.  The aqueous glucose standards were collected and transferred with the same 
process as a tear sample; the capillary was touched to the solution surface and was filled by 
capillary action.  For studies involving larger volumes of stimulated tears, the subject chopped 
onions until tearing was induced.  These tears were collected by capillary action with glass 
Pasteur pipettes (2 mL) and pooled for each subject in order to analyze a homogeneous sample. 
Immediately after collection, the tear sample was transferred to a glass vial (Agilent, Palo 
Alto, USA) with a glass insert (Restek, Bellafonte, USA) containing 10 μL of acetonitrile 
(Mallinckrodt Baker, Inc., Phillipsburg, USA) and 10 μL of an aqueous stock solution of 
isotopically labeled glucose (D-glucose-6,6-d2, 99% labeled, Cambridge Isotope Laboratories, 
Andover, USA) used as an internal standard.  A typical value for the concentration of the D-
glucose-6,6-d2 stock solution was 27.5 μM, corrected for the 99% labeling (leading to a D-
glucose-6,6-d2 concentration of 13.1 μM in the sample injected into the mass spectrometer).  The 
vials were then shaken and centrifuged for five minutes to ensure mixing and that the liquid was 
collected at the bottom of the vial.  The samples were refrigerated at 5oC until analyzed.   
Glucose concentrations were measured using ESI-MS.  Samples were analyzed by flow 
injection analysis on a HP 1000 LC-MS (Agilent, Palo Alto, USA).  Initial studies used an 
autosampler connected directly to the mass spectrometer.  However, our optimized method used 
a 2 μm filter and a Nova-Pak C18 3.9 x 150 mm column (Waters, Milford, USA) placed in-
between the autosampler and the mass spectrometer.  In both methods, the mobile phase 
consisted of acetonitrile and water with 0.1% formic acid (Mallinckrodt Baker, Inc., 
Phillipsburg, USA) with a constant flow rate of 0.2 mL/min.  The ratio of water to acetonitrile 
was 1:1 in the absence of the column and 17:3 with the column.  The ion chromatograms of 
sodiated glucose isotopes (m/z 203 for natural glucose and m/z 205 for D-glucose-6,6-d2) were 
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selected from the total ion chromatogram using the ChemStation software (Rev. A.06.03 [509]).  
These selected ion chromatograms were integrated to provide peak areas for the two glucose 
signals.  During integration, the software option “baseline hold” was used.  The peak areas of m/z 
203 and 205 were used to determine the glucose-to-D-glucose-6,6-d2 ratio.  When calculating the 
peak area ratio, we took into account the 1.3% m+2 natural isotopic contribution of 
Na+(glucose), m/z 203, to m/z of 205; 1.3% of the observed glucose peak area of m/z 203 was 
subtracted from the observed m/z 205 peak area to determine the area due solely to the internal 
standard.  Each sample was injected three times at 6.5 μL per injection and the average glucose 
concentration recorded.  All human samples were collected through protocols approved by the 
University of Pittsburgh Institutional Review Board. 
2.3 RESULTS AND DISCUSSION 
The cationization of glucose with H+, Na+, K+, or Pb2+ was examined.  An initial survey 
comparing negative ion to positive ion ESI suggested greater promise with positive ion methods.  
With the exception of sodium, millimolar concentrations of the acid or salt were needed to 
observe the glucose cation adducts as the base peak.  The sodium-glucose adduct was present in 
all of the spectra and in the majority of them was the most abundant ion.  Since sodiated glucose 
dominated even without the addition of sodium and since tear fluid contains ~160 mM of 
sodium,23 our glucose analysis is based on the sodiated glucose ion.  Further experiments were 
conducted to ascertain the solvent composition (water, acetonitrile, and methanol) that provided 
the maximum signal for sodiated glucose.  Based on the results of these experiments, a 1:1 ratio 
of water to acetonitrile for the sample solvent was selected.  For the experiments without the use 
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of the Nova-Pak C18 column, the 1:1 solvent ratio was also used for the mobile phase with the 
addition of 0.1% formic acid to the aqueous phase to produce more stable baseline ion currents.  
In our initial work, 13C6-glucose was used as an internal standard but an unidentified peak at m/z 
209 (which would interfere with the detection of sodiated 13C6-glucose) was observed in the 
absence of the internal standard.  Therefore, D-glucose-6,6-d2 was a superior alternative since no 
signal was observed at m/z 205 in the absence of the internal standard. 
With the optimal solvents and internal standard established, the effect of the biological 
matrix on the glucose signal was examined.  The sodiated-glucose signal intensity observed for 
both artificial and real tear fluid was low compared to the background signal in our initial studies 
in which samples were directly infused into the mass spectrometer.  Addition of a C18 column 
separated proteins, such as lysozyme, globulin, and albumin, and excess salts from the elution 
time of glucose.  This in-line purification increased both the sensitivity and signal-to-noise ratio 
for sodiated-glucose.  Analysis of the blank (a protein-free glucose-free artificial tear solution4) 
showed an average glucose concentration of 0.98 ± 0.56 μM.  With the use of the column the 
statistical limit of detection was lowered to 3 μM.  These improvements occurred in the presence 
of the column with the mobile phase optimized at a solvent ratio of 17:3 of water with 0.1% 
formic acid to acetonitrile which maximized the glucose signal and minimized overlapping 
peaks.   
The precision of the micro-capillaries was measured by gravimetric means.  Five 
individual capillaries were weighed, filled with water at 20oC, and weighed again.  The average 
value for the water contained in the capillaries was 1.008 ± 0.013 mg (1.011 ± 0.013 μL at 20oC).  
Therefore, in all of our analysis of tears we assume a collection volume of 1.00 μL.   
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To test the linearity of the method, aqueous solutions with known glucose concentrations 
(0 – 200 μM) were prepared and analyzed.  The linear regression of measured versus added 
glucose gave an equation of y = 0.99 x – 0.78 (R2 = 0.98).  The increase in the relative sodiated 
glucose signal m/z 203 can be easily seen when the mass spectra are normalized to the sodiated 
D-glucose-6,6-d2 signal m/z 205 (Figure 2.1). 
 
Figure 2.1.  Eleven spectra of aqueous solutions of known glucose concentrations (0 – 200 μM) with 
intensities normalized to the internal standard D-glucose-6,6-d2 signal intensity at m/z 205.  The 
linear regression of the experimental glucose concentration verses the known glucose concentration 
provided the best fit equation of y = 0.99 x – 0.78 (R2 = 0.98). 
 
The mass spectral measurement over time of the glucose concentration in the 1:1 ratio of 
water-to-acetonitrile was examined.  A 200 μM glucose aqueous solution was prepared and 
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sampled multiple times.  These vials were stored in a refrigerator and tested immediately, a few 
hours later, three days later, and one week later.  The average value for all of the samples was 
201 ± 15 μM with no increasing or decreasing trend over storage time (data not shown).   
The reproducibility of the method was determined with the use of a pooled sample of 
onion-induced tears.  Six samples were collected from the pool and analyzed.  The average 
glucose concentration was 211 ± 8 μM in this stimulated tear sample (data not shown). 
A recovery experiment was performed on another pooled sample of onion-induced tears.  
The tears were spiked with aqueous glucose solutions to increase the glucose concentration by 0, 
107, 233, and 352 μM.  Linear regression of measured versus added glucose gave an equation of 
y = 0.99 x + 256 (R2 = 0.99) (Figure 2.2).  We also determined that the induced tear fluid 
contained 256 μM glucose. 
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 Figure 2.2.  Duplicate samples of pooled, induced tears at four different concentrations of added 
glucose were analyzed.  Error bars are plus/minus one standard deviation from the average value of 
each sample.  Linear regression analysis gave an equation of y = 0.99 x + 256 (R2 = 0.99) and a 
recovery range of 94% to 111% of the glucose spike. 
 
The average relative standard deviation over the three 6.5 μL injections of the diluted tear 
samples studied with concentrations greater than 50 μM glucose was 4%.  For the samples 
studied with concentrations less than 50 μM glucose, the average relative standard deviation of 
the three measurements was 15%.  The FDA currently requires self-blood-glucose monitors to 
have an accuracy of within 15%.  Within one standard deviation, the calibration curve is 
indistinguishable from y = x and the recovery experiment shows 100% recovery of added 
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glucose.  We therefore feel confident using D-glucose-6,6-d2 as the internal standard and the y = 
x calibration curve to determine tear glucose concentrations. 
 We performed two studies on a non-diabetic subject who fasted overnight.  During both 
sessions, which were separated by one week, three samples were taken from each eye.  Samples 
from the same eye were collected at ten minutes intervals.  The tear glucose concentration from 
this subject during the two sessions ranged from 13 to 51 μM with an average of 32 μM (Table 
2.1).   
 
Table 2.1. Tear Glucose Concentration in μmol/L of a Non-diabetic Subject 
 Session 1 Session 2 
Sample Left Eye Right Eye Left Eye Right Eye 
1st 22 38 44 48 
2nd 51 37 50 25 
3rd 13 17 14 24 
 
 
The concentration of tear glucose determined in this work for this non-diabetic subject is 
about four-fold less than the tear glucose concentrations recently reported.8  Whereas previous 
studies used collection methods which either touched the eye or chemically stimulated tears,7,9,10 
we use glass micro-capillaries to collect a single microliter volume of tear fluid from the tear 
meniscus without touching the eye.  This decrease in reported tear glucose concentration is likely 
due to our less irritating method of tear collection.  The onion-stimulated tears (from a different 
subject) showed a seven to eight fold higher glucose concentration than in the absence of 
stimulation. 
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2.4 CONCLUSION 
In the present study we demonstrate a robust ESI-MS method for determining tear glucose 
concentration in tear fluid.  Liquid chromatography separates glucose from the majority of salts 
and proteins, such as lysozyme, globulin, and albumin, in tears reducing interference of the 
biological matrix on the sodiated-glucose signal.  The resulting increase in the sensitivity and 
signal-to-noise ratio of glucose over data obtained without the column allows measurements of 
tear glucose concentrations as low as 10 μM (limit of quantification) by relying on an internal 
standard.  We use a 1μL tear sampling method that is minimally irritating to the eye.  This 
method enables reliable studies of physiological tear glucose concentrations in non-stimulated 
tears.  A preliminary study indicates that the physiological, baseline tear glucose concentration is 
substantially below previous reports.  Further studies are warranted to determine the inter- and 
intra-individual variation in baseline tear glucose concentration.  This method will be used to 
establish normal values for tear glucose concentration and can monitor changes in tear glucose 
with changes in blood glucose.  Application of this LC-MS method can help us to understand 
tear glucose physiology.  Our future work will determine whether monitoring tear glucose 
concentration is a viable approach for non-invasive blood glucose monitoring.  We are now 
using this method for tear glucose concentration measurements to examine a population of non-
diabetic and diabetic subjects to determine their tear fluid glucose concentrations and their 
correlations of tear glucose with blood glucose. 
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3.0  MASS SPECTRAL DETERMINATION OF FASTING TEAR GLUCOSE 
CONCENTRATIONS IN NONDIABETIC VOLUNTEERS 
Baca JT, Taormina CR, Feingold E, Finegold DN, Grabowski JJ, Asher SA. Clin Chem 2007; 
53:1370-1372. 
3.1 INTRODUCTION 
Glucose has been a recognized component of tear fluid since the early 1900s, but disagreement 
continues regarding its concentration in tear fluid and its correlation with blood glucose 
concentration.1-6  Literature reports of normal tear glucose concentrations range between 0 and 
9.1 mmol/L (164 mg/dL), with median values of 110 to 280 μmol/L (1.98 and 5.04 mg/dL).1-7  In 
a recent study of 121 persons tear glucose concentrations ranged from below the limit of 
detection to 9.1 mmol/L (164 mg/dL).  Much of the difference in reported tear glucose 
concentrations is likely due to use of different tear collection techniques.8  Collection techniques 
causing severe eye irritation [such as filter paper collection6] are associated with the highest tear 
glucose concentrations, whereas less irritating techniques (such as glass capillary collection) are 
associated with the lowest.2,3  Chemically stimulated tears have increased tear glucose.8,9  
Reliable tear sampling may also be confounded by individual differences in tolerance to real or 
expected eye stimulation during sampling.   
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Improved tear fluid collection, and the ability to analyze very low volumes of tear fluid, 
may dramatically improve measurement of tear fluid glucose concentrations and help resolve the 
reported discrepancies in basal tear glucose concentrations.  Improved methods would also 
enable the study of physiologic glucose transport in the eye and advance the use of tear fluid as a 
surrogate for blood in measuring other clinically important analytes.  
Some groups have tried to use tear glucose to diagnose diabetes,4,5 and others have 
proposed continuous monitoring of blood glucose concentrations by use of contact lenses with 
glucose sensors.10-13  We recently reported a photonic crystal glucose-sensing material for 
noninvasive monitoring of glucose in tear fluid.10  Detailed understanding of tear glucose 
concentration and its regulation is critical to developing noninvasive glucose sensors.   
We recently developed an ESI-MS method for measuring glucose in 1 μL samples of 
collected tear fluid.9  Using this method, we studied here basal tear glucose concentrations in 
healthy persons without diabetes. 
3.2 EXPERIMENTAL 
We recruited volunteers (age 18-60 years) within and around the University of Pittsburgh. 
Persons with a history of diabetes were excluded.  Blood and tear samples were obtained after 
participants had fasted overnight for at least 8 hours.  The samples were always collected in the 
same order: capillary blood from the finger pad, tear fluid from the left eye, and then tear fluid 
from the right eye.  This sequence was repeated 3 times for each study participant, with at least 
10 minutes between successive blood sample collections.  Glucose in capillary blood was 
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measured with an Accu-Chek® Compact glucometer (Roche), according to the manufacturer’s 
protocol.  
A total of 26 volunteers completed the study; 11 wore their usual contact lenses at the 
time of the study, and 15 did not wear contact lenses.  The type of contact lenses worn were daily 
disposable (n=1), daily wear (n=6), extended wear (n=1), and silicone hydrogel lenses (n=2).  Of 
the 15 non-contact lens wearers, 1 had a history of contact lens use, but did not wear contacts on 
the day of the study.  For 1 contact lens wearer, the collected tear samples were lost because of 
vial breakage before analysis.  For 2 participants (1 from the contact lens group and 1 from the 
non-contact lens group), 1 of the 6 tear glucose samples was lost because of instrument failure. 
The tear glucose concentration statistics for these 2 participants were determined from only 5 
samples.  All clinical procedures were approved by the University of Pittsburgh School of 
Medicine IRB, and all participants signed a detailed informed consent form. 
Tear fluid samples of 1 µL were collected and analyzed by LC electrospray ionization 
mass spectrometry (ESI-MS) as previously reported.9  Three aliquots of each tear sample were 
injected into the analyzer to determine the mean glucose concentration.  Our study found much 
lower tear fluid glucose concentrations for healthy individuals than did previous studies (Figure 
3.1). 
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 Figure 3.1. The six tear glucose concentrations determined for each subject are plotted against the 
subject’s average blood glucose concentration.  All tear glucose measurements for a given subject are 
hence in vertical alignment.  Large variations occur in the value of the tear glucose concentrations 
for each subject between their eyes and between subsequent measurements of each eye over the 
course of the study (30-40 minutes).  It should be noted that in all cases blood glucose concentration 
remains essentially constant over the measurement interval as subjects had fasted overnight.  The 
average relative standard deviation of the three blood glucose measurements for each subject was 
4%. 
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3.3 RESULTS AND DISCUSSION 
The population median (range) of the tear glucose concentrations were 28 (7–161) µmol/L [0.50 
(0.13–2.90) mg/dL].  The distribution of mean tear glucose concentrations was highly skewed; 
<28 µmol/L (0.50 mg/dL) in 50% of the study participants and <42 µmol/L (0.76 mg/dL) in 
80%.  Two individuals were observed rubbing their eyes during the course of the study, and they 
had the highest mean (SD) tear glucose concentrations: 128 (75) and 161 (71) µmol/L or 2.31 
(1.35) and 2.90 (1.28) mg/dL.   
Because the SD of the mean tear glucose concentration for each participant was 
proportional to the mean for each participant, a natural log transformation was applied to the tear 
glucose concentration values (Figures 3.2 and 3.3).  After transformation, standard statistical 
methods were applied. 
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 Figure 3.2.  The standard deviations of the six tear fluid glucose measurements for each subject are 
linearly proportional to the mean value measured (~50% of the mean value). After natural log 
transformation, standard statistical analysis methods can be applied to the transformed data. 
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 Figure 3.3.  The transformed tear glucose values of the six tear glucose determinations for all 
subjects are plotted against the subject’s average blood glucose concentration.  There is significant 
variation in the tear glucose concentration measured in individual subjects over the course of the 
study (30-40 minutes).  Note that all tear glucose measurements for a given subject are in vertical 
alignment.  The average natural log transformed tear glucose value for non-contact-wearing subjects 
was 3.1 ± 0.8, and 3.2 ± 0.8 for contact-wearing subjects (mean ± SD). 
 
Contact lens use did not affect mean tear glucose (p=0.715).  Transformed tear glucose 
concentrations were significantly correlated with mean blood glucose (R=0.50, p=0.01, Figure 
3.4a).  This correlation for fasting tear and blood glucose is similar to that reported by Daum and 
Hill1 of R=0.53 for blood and tear glucose measurements variations throughout the day. 
However, they reported a mean (SD) population tear fluid glucose concentration of 420 (355) 
µmol/L or 7.57 (6.40) mg/dL.  
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The glucose concentrations in the right and left eyes were highly correlated within 
individuals (Figure 3.4b).  There was no evidence that eye-to-eye variation in individual study 
participants differed significantly from variation in a single eye over time. Furthermore, we 
observed no evidence that variation in tear glucose concentration between individuals with 
similar blood glucose concentrations was greater than variation in tear glucose concentration 
within an individual. 
30 
3.8 4.0 4.2 4.4 4.6 4.8 5.0 5.2 5.4 5.6 5.8 6.0 6.2 6.4 6.6
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
Contact Lens Wearers
Linear Fit
Non-Contact Lens Wearers
Linear Fit
Av
er
ag
e 
ln
(T
ea
rG
lu
co
se
 C
on
ce
nt
ra
tio
n 
/ µ
m
ol
/L
)
7
20
55
148
a
1
2
3
4
5
Average Blood Glucose (mmol/L)
1 2 3 4 5 6
6 y = x
ln
(L
ef
t E
ye
 T
ea
r G
lu
co
se
 / 
µm
ol
/L
)
ln (Right Eye Tear Glucose / µmol/L)
b A
ve
ra
ge
 ln
(T
ea
rG
lu
co
se
 C
on
ce
nt
ra
tio
n 
/ µ
m
ol
/L
)
ln
(L
ef
t E
ye
 T
ea
r G
lu
co
se
 / 
µm
ol
/L
)
ln
(L
ef
t E
ye
 T
ea
r G
lu
co
se
 / 
µm
ol
/L
)
 
Figure 3.4.  a) Correlation (p = 0.01) between the mean ln(tear glucose concentration) and the mean 
blood glucose concentration  A linear regression for all subjects gives y = 0.80x – 1.07 (R = 0.50).  
Linear regression for the subpopulations of contact wearers and non-contact wearers gives y = 
0.570x + 0.332 (R = 0.22) for contact lens wearers and y = 0.961x - 2.079 (R = 0.70) for non-contact 
wearers. b) Paired tear glucose observations within study participants. No significant differences 
were observed between right and left eyes (p = 0.76 2-tailed paired t test), but results may differ at 
any given time.  The left and right tear glucose determinations that are closest in time are plotted 
against each other.  There are hence 3 data points for each study participant.   
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The correlation between the transformed tear glucose value and the average blood 
glucose concentration appears to be stronger for non contact lens wearers than for subjects 
wearing contact lenses (R=0.70 vs. R=0.22). However, analysis of covariance does not indicate a 
significant difference (p=0.63).  
The ESI-MS method used here enables reliable determination of basal tear glucose 
concentrations in fasting individuals.  Study participants had fasted overnight, and had stable 
blood glucose concentrations over the brief course of the study.  We observed much lower basal 
tear glucose concentrations than previously reported for healthy individuals.  This difference is 
likely due to our sampling methods, which were less irritating than earlier methods that 
stimulated tear production chemically or with filter paper.8  If our collection method had caused 
significant irritation, we would have expected tear glucose concentrations to increase over the 
course of the study.  We observed no evidence of such an increase (Figure 3.5). 
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 Figure 3.5.  A plot of the relative difference in tear glucose concentration from the average tear 
glucose value for each subject versus time does not show a significant trend.  If the sampling 
procedure caused significant irritation to the eye, we would expect an overall relative increase in tear 
glucose concentration with time. 
 
We observed significant variation in tear glucose concentrations between the 2 eyes of 
individual study participants, as well as over time within a single eye.  During this study we were 
cognizant of potential confounding events such as yawning and eye rubbing.  Although the 2 
individuals who rubbed their eyes during the study had the highest glucose concentrations, 
events like these do not explain the large within-individual differences observed.   
Variations in tear glucose concentrations within a single individual must derive from the 
sum of the biological variance and any variances associated with sampling and measurement.  
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The error in our tear fluid collection volumes was negligible9; the SD observed for an individual 
was ~3 times the SD of the 3 replicate mass spectral measurements of a single tear fluid sample.  
The relative SD of these three replicate varies somewhat with glucose concentration but has a 
median value of 14%.  Thus, the observed SD in tear glucose measurements derives mainly from 
actual variations of the glucose concentration in the different tear fluid samples.   
We did not observe a systematic increase over time in glucose concentration variations 
that could result from the effect of tear depletion during repeated measurements.  Tear glucose 
concentration appeared to vary randomly over the repeated sampling events. 
3.4 CONCLUSION 
We observed variations in tear glucose concentrations among fasting individuals and a 
significant correlation between ln(tear glucose concentration) and blood glucose concentration.  
Mean fasting tear glucose concentrations did not differ significantly in relation to contact lens 
use. Further studies are needed to investigate the apparent difference in the correlation between 
tear glucose and blood in these subpopulations.   
The extremely low glucose concentrations in tear fluid, more than 100 times lower than 
in blood, raise questions about the physiologic role of tear glucose.  Future studies are needed to 
address the correlation between tear and blood glucose in hypoglycemic and hyperglycemic 
states and in the presence of diabetes.      
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4.0  TEAR GLUCOSE ANALYSIS FOR THE NON-INVASIVE DETECTION AND 
MONITORING OF DIABETES 
Baca JT, Finegold DN, Asher SA. The Ocular Surface 2007; Submitted 
4.1 INTRODUCTION 
According to the most recent statistics available, approximately 20.8 million people in the United 
States, or about 7% of the population currently has diabetes.1  Worldwide, over 180 million 
people have diabetes, and the prevalence of this disease is expected to double by 2030.2  The 
economic cost of diabetes in the United States alone is about $132 billion or about 10% of 
healthcare expenditures.3
The Diabetes Control and Complications Trial clearly demonstrated that tight glycemic 
control is critical in managing diabetes and preventing complications such as retinopathy, 
nephropathy, and neuropathy.4  In order to control blood glucose levels, current standards of care 
require self-monitoring of glucose several times a day, with increased frequency for patients 
receiving insulin.5  Currently, self-monitoring of blood glucose requires a finger-stick blood 
sample for direct measurement of glucose.  While many non-invasive approaches to blood 
glucose monitoring have been investigated, none have been able to replace the direct 
measurement of glucose.6  Implantable, continuous glucose sensors have shown promise for 
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improving glycemic control.7,8  However, currently approved devices must be calibrated at least 
twice a day with a direct blood measurement, and must be replaced after 3-7 days.  Non-invasive 
glucose monitoring approaches under development include IR spectroscopy,9,10 Raman 
spectroscopy,11,12 measurement of optical polarization rotation,13 photoacoustic phenomena,14 
optical coherence tomography,15 fluorescence measurements,16,17 surface-plasmon resonance in 
nanoparticles,18 and electrical impedance measurements.19  A single non-invasive device for 
monitoring blood glucose, the GlucoWatch (Cygnus, Redwood City, CA), has been approved by 
the FDA for supplementary blood glucose monitoring.  However, results from the GlucoWatch 
must be frequently checked against direct blood glucose measurements.  Additionally, recent 
studies have found that adding GlucoWatch monitoring to standard self-monitoring of blood 
glucose did not result in improved glycemic control.20   
One approach to non-invasive monitoring of blood glucose is to monitor the 
concentration of glucose in a more accessible surrogate fluid such as tears.  Tear glucose in 
diabetic patients has been studied for over 80 years.21  The fairly recent development and 
widespread use of contact lenses has motivated ideas for using contact lenses in tear glucose 
analysis for the detection or monitoring of diabetes.  At least three independent groups have 
developed glucose sensors that can be incorporated into contact lenses.22-25  The safety of daily 
wear soft contact lenses in diabetic patients has recently been demonstrated,26,27 suggesting that 
contact lens monitoring is potentially a viable supplement or alternative to blood glucose 
monitoring.  In order for this approach to be successful a detailed understanding of how blood 
and tear glucose concentrations correlate and the underlying physiology of glucose secretion into 
tears are necessary.  Unfortunately, there is at present, significant disagreement as to the absolute 
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concentrations of tear glucose in normal and diabetic subjects, as well as to whether tear glucose 
concentrations correlate with blood glucose concentrations.   
Reported values for tear glucose in normal individuals range from 0 to 3.6 mM (65 
mg/dL),28 while concentrations as high as 84 mg/dL (4.7 mM) have been reported for diabetic 
persons.21  The reported tear glucose concentrations are generally lower when the analytical 
techniques require smaller tear volumes.  Recently, median glucose concentrations of 89 μM 
have been measured in 5 μL tear samples,29 while concentrations of 28 μM have been measured 
in 1 μL tear samples,30 all from fasting, non-diabetic individuals.  While older studies generally 
measured glucose in larger volumes of chemically or mechanically stimulated tears, most recent 
studies specifically try to avoid conjunctival irritation and tear stimulation (Figure 4.1).  
While the effect of the collection method on the tear glucose concentration has been 
considered,31 there has been little clarification of the discrepancies in reported tear glucose 
concentrations.  The recent interest in developing in situ tear glucose monitors has motivated this 
review of the current state of glucose sensing in tear fluid. 
Figure 4.1.  Summary of average tear glucose concentrations found in non-diabetic subjects from 1930 to present.  Studies are grouped by the 
type of stimulation used to induce tearing (chemical, mechanical, and non-invasive).  These are arranged in chronological order from left to 
right within each section.  The details of each study are discussed in the tables and text below.  Note that studies employing mechanical 
stimulation measure the highest tear glucose concentrations. 
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4.2 TEAR PRODUCTION AND GLUCOSE TRANSPORT 
The tear glucose concentration is determined by the amount of glucose and the volume of the 
aqueous tear fraction.  Changes in the transport of water in and out of the tear film have as much 
or greater effect on the tear glucose concentration as changes in glucose transport into the tear 
film.  The structure and function of the tear film, especially as these relate to the regulation of the 
aqueous tear volume is central to the determination of tear glucose concentration. 
The tear film on the surface of the eye is composed of several layers.  Most superficially 
is a lipid layer that is less than 100 nm thick and serves several functions including preventing 
evaporation of the underlying aqueous layer and providing a smooth optical surface over the 
cornea.32  This layer is comprised of sterol esters, wax esters, and many other minor lipid 
components.33  These are secreted from the meibomian glands located on the margins of the 
eyelids, just posterior to the eyelashes.  Dysfunction of these glands can lead to increased 
evaporation of tears from the eye, causing an increased tear osmolarity and clinical dry eye.34  
The lipid layer is compromised when contact lenses are worn; this layer may be completely 
absent over rigid contact lenses.33
Just below the lipid layer is the aqueous fraction.  Measurements of the thickness of this 
layer over the cornea vary from 2.7 μm to 46 μm, with the most recently reported value of 3.3 
μm.35  One difficulty in measuring the thickness of this layer is that it changes immediately after 
a blink, thinning as it distributes over the surface of the eye.35  In the presence of contact lenses, 
the aqueous tear film can be measured both in front of the contact lens (pre lens), and between 
the lens and the cornea (post lens).  Both the pre lens and post lens tear films are measured to be 
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approximately 3 μm thick.35  In both the presence and absence of contact lenses, the tear film is 
considerably thicker near the margins of the eyelids, where a meniscus forms.  The total volume 
of the aqueous tear film is about 7 μL,36 and its production and elimination are discussed below. 
Below the aqueous layer of the tear film is a mucin layer, consisting of glycoproteins 
which lubricate the surfaces of the eye.  At least 20 different mucins are present in this layer.  
They provide a hydrophilic surface, over which the aqueous fraction can rapidly flow.37,38  This 
layer is approximately 30 μm thick32 and its components are produced by both the cornea and 
conjunctiva.39  The mucin layer moves freely over the glycocalyx, which is comprised of 
membrane-associated mucins bound to the cornea and conjunctiva.   
4.2.1 Production and elimination of aqueous tear fluid 
The rate of tear production can vary by a factor of over 100 between basal tear production 
and active tearing.40  By studying the clearance of fluorescein, Mishima et al. estimated the 
average rate of tear fluid production to range between 0.5 and 2.2 µL/min (with an average of 1.2 
µL/min) at baseline.36  After the introduction of fluorescein, a rapid decrease in fluorescence was 
observed that was ascribed to reflex tearing.  After about five minutes, the fluorescein clearance 
rate decreased to about 17% per minute.  Calculation of the “unstimulated” tear production was 
based on the lower fluorescein clearance rates seen at later times.36
While estimates of the rate of baseline tear fluid production have not varied significantly 
since the 1966 report of Mishima et al., the relative contributions of different sources to the 
aqueous tear fraction continues to be debated.  Traditionally, aqueous tear fluid was thought to 
be almost entirely produced by the main lacrimal gland with very minor contributions from the 
accessory lacrimal glands and goblet cells in the conjunctiva.41  Recent studies, however, have 
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shown that the rate of water flow across the conjunctiva can be as high as 1-2 µL/min and may 
account for a large proportion of basal tear production.42  While estimates of the contribution of 
conjunctival secretion to basal tear fluid production vary widely, recent models of tear 
production suggest that 25% of tear fluid is produced by the conjunctiva in the absence of reflex 
tearing.43  While the aqueous fraction in stimulated tears is derived primarily from the lacrimal 
glands, the aqueous fraction in unstimulated tears may have a significant conjunctival source.  
The elimination of the aqueous fraction of tears can also influence the concentration of 
tear fluid analytes.  The major routes of elimination for aqueous tears are drainage through the 
lacrimal canaliculi to the nasolacrimal duct and evaporation.41  Under certain conditions, 
conjunctival or corneal absorption of water can contribute to the elimination of aqueous tears.43  
During a blink, tears are swept from the lateral canthus toward the medial canthus.44  Tears then 
pass into the lacrimal canaliculi, which connect to the lacrimal sac.  The tears then drain by 
gravity through the nasolacrimal duct and into the inferior nasal meatus.44  Blockage of this 
drainage system by cautery or with plugs increases the basal tear volume, and is a common 
treatment for dry eyes.34
The rate of tear film evaporation is proportional to the surface area of the eye exposed to 
the environment.45  The palpebral fissure, i.e. the distance between the upper and lower eyelids, 
varies between subjects.  It can also be increased by lid surgery or by disease states, such as 
hyperthyroidism.34
Disturbances of the lipid tear film can lead to dramatically increased rates of evaporation.  
When the lipid layer is washed from the eye or the meibomian glands are occluded, the rate of 
evaporation increases from 0.1 μL/min to 1.7 μL/min.32  Rates of evaporation also depend on the 
ambient temperature and humidity.32  As noted above, the lipid layer can be compromised by 
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contact lenses; increased tear evaporation is observed during contact lens use.40  This increase in 
evaporation does not appear to vary significantly with contact lens composition or level of 
hydration.46  The average increase in the rate of evaporation during contact lens wear is about 
35%, however the rate of evaporation may vary significantly between subjects.46  
4.2.2 Glucose transport in tear fluid 
The source of glucose in tears remains unclear.  Explanations for the mechanisms of 
glucose transport into the tear fluid have changed as different tear glucose concentrations were 
observed.  The studies that used mechanically irritative methods to obtain tear fluid found the 
highest glucose concentrations.  These studies also found a correlation between blood and tear 
glucose concentrations.31,47-49  Mechanical irritation abrades the conjunctiva and probably results 
in the leakage of glucose from epithelial cells or the interstitial space directly into the tear 
fluid.31,41   
Studies that attempt to avoid abrasion of the cornea and stimulation of tearing measure 
the lowest glucose concentrations.29-31  It has been suggested that exclusion of glucose from tear 
fluid aids in preventing bacterial infections of the exterior eye.50  Many of the studies of 
chemically stimulated tears find very low concentrations of glucose, suggesting that very little, if 
any, glucose comes from the lacrimal glands.31,48,50  
There is only limited evidence for glucose transporters in the tear glands, the conjunctiva, 
and the cornea.  The constitutive glucose transporter, GLUT-1, is present in the apical corneal 
epithelium,51 but absent in the lacrimal glands and conjunctiva.52  Expression of GLUT-1 in the 
corneal epithelium is increased after corneal abrasion, and appears to have a role in corneal 
wound healing.53  A sodium/glucose cotransporter, SGLT-1, is present on the apical side of the 
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bulbar and palpebral conjunctiva.54,55  This transporter operates in both directions, allowing both 
secretion and absorption of glucose, depending on sodium and glucose concentrations.56  While 
this transporter removes glucose from the tear fluid under physiological conditions,57 it can add 
glucose to the tear fluid during the hypoosmotic stress that occurs when rinsing the eye with 
water or after swimming.28,43,56,57   
Recent models of electrolyte and metabolite transport in the tear fluid suggest that a 
paracellular transport mechanism is required to fully explain observed electrolyte 
concentrations.43  Studies of polyethylene glycol oligomer permeability in the cornea and 
conjunctiva of rabbits suggest that there are paracellular pores with diameters of ~ 4 nm and ~ 2 
nm in the conjunctiva and cornea respectively.58  While glucose should be able to pass though 
these pores and into the tear fluid, its transit has not been directly measured.  While the 
distribution and regulation of glucose transporters affecting the tear glucose concentration is not 
yet fully characterized, glucose transport across the conjunctiva appears to be the major 
determinant of tear glucose concentration in the absence of reflex tearing. 
4.2.3 Stimulated tears 
Increased aqueous tear volumes can be caused by increased tear production (lacrimation) 
or by decreased tear elimination, which may be caused by obstruction of the tear drainage system 
or paralysis of the muscles responsible for sweeping tears towards the puncta.44  Some authors 
have questioned the existence of a true basal tear production rate, suggesting that all tears are 
“stimulated.”59  This argument is based on the fact that the rate of tear production decreases 
dramatically with the administration of anesthesia.  However, while tear production from the 
lacrimal gland may require stimulation, the epithelial cells of the conjunctiva continuously 
45 
secrete water and ions in response to electrolyte and metabolite concentration gradients.57  The 
rate of aqueous tear production can increase over 100-fold in response to a variety of physical or 
chemical stimuli; the changes in aqueous tear production may alter the chemical composition of 
tear fluid.40   
In a 1981 review of tear biochemistry, Van Haeringen recounted several methods of 
inducing tearing in order to increase the sample volume.41  Chemical stimulants of lacrimation 
include onion vapors, ammonia, formalin, benzyl bromide, chloracetophenone, and 
bromoacetone.41  Cigarette smoke and onion vapors have also been used to stimulate tearing.41,60  
Mechanical stimulation of the conjunctiva or cornea with absorbent materials such as filter 
paper, cellulose sponges, and cotton thread is also commonly used to increase tear 
production.41,47,49  Because these methods can abrade the conjunctiva, which could alter analyte 
concentrations, other methods of stimulating lacrimation that do not directly contact the 
conjunctiva have been investigated.  These include stimulating the nasal mucosa, inducing a gag 
reflex with a tongue depressor, having subjects look into the sun, and inducing emotional 
tearing.40,41,59   
Lacrimation in response to physical and chemical stimulation of the ocular surfaces or 
photo stimulation of the optic nerve is mediated by a reflex arc.  Activation of afferent sensory 
nerves in the conjunctiva, cornea, nasal mucosa, or optic nerve leads to reflexive stimulation of 
efferent sympathetic and parasympathetic nerves innervating the lacrimal gland.61,62  While 
neurotransmitters from the autonomic efferent nerves such as acetylcholine and norepinephrine 
are the most potent stimulants of tearing, many other minor neuromediators have been identified 
and recently reviewed.62,63  Recent immunohistochemical studies suggest that there is direct 
parasympathetic enervation of goblet cells in the conjunctiva and direct sympathetic enervation 
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of stratified squamous cells in the conjunctiva.39  Therefore, transport of fluid and mucins 
directly across the conjunctiva may also lead to increased tear volume and mucin secretion after 
mechanical stimulation of the conjunctiva.   
It is clear that reflex tearing must be avoided if basal tear glucose concentration is to be 
accurately measured.  In practice, this is very difficult because only small volumes of basal tear 
fluid are available.  Individuals may respond differently to even the most benign collection 
techniques; the mere discussion of tear fluid collection is sufficient to stimulate tearing in some 
subjects.  There may also be uncontrolled and unrecognized variables affecting tear stimulation 
in different subjects such as changes in room temperature or humidity from day to day.  In 
addition to all of these issues, contact lens use can cause irritation and stimulate tear 
production.40  This could alter the relevant basal tear glucose concentration measured by a 
contact lens-based glucose sensor.  As contact wearers become habituated to their lenses, 
however, this irritation, as measured by blink frequency, decreases.40
4.2.4 Effects of diabetes on tear glucose transport 
Most studies of tear physiology have been conducted on non-diabetic animals and 
humans.  If tear glucose analysis is to be used to detect or monitor diabetes, we must consider the 
effects of diabetes on aqueous tear production and glucose transport in tear fluid.  While the 
relative importance of different molecular mechanisms in diabetes pathogenesis is debated, the 
increased intravascular concentration of glucose that results from diabetes ultimately leads to 
microvascular and nerve damage.64,65  In light of the above discussion of aqueous tear film 
production, damage to either the vasculature supplying blood to the eye or the nerves of the 
lacrimal reflex arc might be expected to alter tear production.   
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Keratoconjunctivitis sicca, or dry eye, can be caused by decreased tear production, or 
alterations in the tear fluid such as loss of the lipid layer, leading to increased tear osmolarity.  
Dry eye is more common in diabetic patients, and correlates with poor glycemic control as 
measured by mean annual hemoglobin A1c (HbA1c) levels.66  When measured by fluorescent 
dye clearance, basal tear secretion rates are indistinguishable in control and diabetic subjects.67,68  
Reflex tearing, as measured by a Schirmer test without anesthesia, is decreased significantly in 
diabetic subjects.67  This decrease in reflex tearing may be due to a decreased sensitivity of the 
conjunctiva resulting from neuropathy.69  During episodes of hyperglycemia, increased 
osmolarity in the extracellular fluid may also impede aqueous tear flux across the conjunctiva or 
into the lacrimal gland.66  Other differences noted in the eyes of diabetic subjects include a 
decreased tear break-up time, loss of mucin secreting goblet cells, and squamous metaplasia of 
the conjunctiva, indicating chronic irritation.69  Overall, diabetes can effect tear composition and 
the structure and function of the tissues that contribute to aqueous tear production. 
Increased tear glucose concentration in diabetic subjects has been repeatedly 
demonstrated.21,29,47-49,70-73  However, many of these studies used filter paper to collect the tear 
sample, and the observed high glucose levels may be due to intercellular fluid leaking through 
the abraded conjunctiva.31  A recent study of tear glucose concentration in 50 non-diabetic 
subjects and 33 diabetic subjects specifically tried to avoid chemical or mechanical stimulation 
by collecting tear samples with a glass microcapillary.29  This study observed overlapping ranges 
of tear glucose concentration in fasting normal and diabetic subjects, but found a statistically 
significant increase in average tear fluid concentrations in the diabetic subjects (89 μM for 
normal and 150 μM for diabetic subjects).  While tear glucose concentrations are clearly 
increased in diabetic subjects, the precise mechanism remains unclear.  Studies using sampling 
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methods that cause mechanical stimulation of the conjunctiva are likely to be simply measuring 
analytes in direct equilibrium with intercellular fluid.  Studies of non-stimulated tears may 
measure increased glucose due to paracellular glucose transport in the conjunctiva.  It is also 
possible that these studies were not entirely successful in avoiding contact with the eye during 
sampling with glass microcapillaries over the required five minute sampling periods.29,31
4.3 MEASUREMENT OF TEARS IN EXTRACTED TEAR FLUID 
The chemical components of tears were first studied by Fourcroy and Vauquelin over 200 years 
ago.74  The first quantitative report of glucose in tear fluid appears to be from 1930, when Ridley 
reported tear glucose concentrations of 3.6 mmol/L (65 mg/dL).75  While the method of glucose 
analysis was not described in this study, the tear volume studied was 0.2 mL, suggesting that 
tearing was induced to collect such large volumes.  Reported values of tear glucose concentration 
have steadily decreased as the analytic methods required less sample volume.  At the opposite 
extreme, LeBlanc et al. recently reported an average tear glucose concentration of 7.25 ± 5.47 
μmol/L in five patients in an intensive care unit.76  Glucose was measured using high 
performance liquid chromatography with pulsed amperometric detection.  The sample volumes 
studied were variable and not individually reported, but were presumably less than 1 μL.77,78  The 
fact that the reported values of tear glucose concentrations have varied by 1000-fold between 
studies demonstrates the need for careful consideration and control of experimental parameters 
such as collection method, analysis method, and selection of the clinical population. 
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4.3.1 Mechanical stimulation 
Because the tear fluid collection method seems to have the greatest influence on the 
reported tear glucose concentrations, we have grouped the previous studies of tear glucose 
concentration by collection methodology.  As noted above, tear collection methods that 
mechanically stimulate, and presumably abrade the conjunctiva, measure the highest levels of 
glucose (Table 4.1). 
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Table 4.1. Mechanical Stimulation in the Study of Tear Glucose Concentration 
 
NORMAL DIABETIC Year Reference Sample 
Collection 
method 
Glucose 
Measurement 
Method 
Volume 
of 
Sample 
[mL] 
Range 
[mM] 
Average 
± std 
[mM] 
patients n Range 
[mM] 
Ave± 
std 
[mM] 
patients n 
1958 Lewis and 
Stephens49
Clinistix King method 0.1 0-2.22 0.78 ± 
0.50 
13 18 0.56-
8.30 
2.90 ± 
1.90 
15 29 
1965 Balik79 filter paper 
strips 
reduction 0.1 0.25-3.3        
1969 Lax80  filter paper 
strips 
enzymatic NA   1.141 ± 
0.159 
32 32     
1971 Motoji81 filter paper 
strips 
glucose 
oxidase 
NA  0.40 ± 
0.09 
32 32  0.80 ± 
0.24 
169 169 
1977 van 
Haeringern  
and 
Glasius31
filter paper 
strips 
glucose 
dehydrogenase 
NA 0.1-1.5* 0.88 10 10 2-10* 5.36 5 5 
1984 Daum and 
Hill82
capillarya glucose 
dehydrogenase 
0.005 1.1-1.4* 1.2* 3 6     
1988 Kang et al.83 Schirmer 
strips 
glucose 
oxidase 
0.01  0.15-0.45 0.25 ± 
0.10 
30 30     
1993 Haeckel et 
al.84  
Schirmer 
strips 
NA NA  0.056       
 
* Estimated from graph 
a Mechanical rubbing of bulbar conjunctiva  
 
 
These studies generally use a filter paper or Schirmer test strip to collect the tear sample.  
Glucose is then extracted from the filter paper and measured enzymatically,31,83 or transferred to 
a glucose oxidase reagent strip and measured “semiquantitatively” by comparing the color of the 
strip to a calibrated color chart.47  More recent investigations have instilled reagent strips in the 
lower conjunctival sac to more directly measure glucose concentration.48,85  A limitation of these 
studies is that color comparison can be subjective, and the subjects could only be stratified into 4 
or 5 arbitrarily defined groups.48,49,71,72  
Van Haeringen and Glasius compared glucose concentrations in the chemically and 
mechanically stimulated tears of normal and diabetic subjects.31  They first stimulated tearing 
with 2-chloracetophenone and collected 20 μl tear samples with a capillary tube.  They then 
collected a second tear sample using filter paper strips.  The tear glucose concentration 
determined using filter paper collection was higher for all subjects.  The increase was between 
0.1 and 1.5 mmol/L for subjects with blood glucose below 10 mmol/L (180 mg/dL) and as high 
as ~9 mmol/L for extremely hyperglycemic subjects with blood glucose concentrations of ~20 
mmol/L (360 mg/dL).  A 1969 dissertation by Lax, which is cited by Van Haeringen and 
Glasius, found glucose concentrations of 0.206 ± 0.027 mmol/L (mean ± SD) using capillary 
collection and 1.141 ± 0.159 mmol/L using filter paper collection in non-diabetic subjects.31,80  
Daum and Hill used capillaries to collect 5 μL tear samples at different times from non-
diabetic subjects after mechanical stimulation of the conjunctiva with a cotton applicator.82  They 
measured an increase in tear glucose concentration from ~0.28 mmol/L (~5 mg/dL) before 
stimulation to a peak value of ~2.5 mmol/L (~45 mg/dL) 10 minutes after stimulation.  Tear 
glucose concentrations remained elevated at 30 minutes, but returned to baseline at 60 minutes.  
This time course suggests that caution must be exercised in planning and interpreting tear 
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glucose studies.  Unrecognized conjunctival stimulation early in a time course study of tear 
glucose may affect many subsequent measurements.  A similar increased tear glucose 
concentration after corneal or conjunctival irritation has also been observed in rabbits.86,87  
Daum and Hill also observed an increase in tear glucose after hypoosmotic stress induced 
by immersion of the eye in distilled water for 60 seconds.82  It is not immediately clear whether 
this should be considered physical or chemical stimulation of tearing.  However, the tear glucose 
response seems similar to that of physically stimulated tears. 
Studies of mechanically stimulated tears generally find a correlation between the tear and 
blood glucose.  This is not surprising as the glucose measured in these studies likely comes 
directly from the interstitial space in the conjunctiva.  Rabbit studies suggest that short term 
contact lens use increases tear glucose concentrations in a manner similar to other means of 
mechanical stimulation.40,87  However, it should be noted that our recent study found no evidence 
of increased tear glucose concentrations in fasting subjects wearing contact lenses.30
4.3.2 Chemical and non-contact stimulation 
Early analytical techniques used to study tear glucose concentration required analyte 
volumes that would take hours to collect at basal rates of tear secretion.  Hence, many studies 
have used a chemical lachrymator to induce tearing and speed sample collection (Table 4.2). 
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Table 4.2. Chemical Stimulation in the Study of Tear Glucose Concentration 
NORMAL† DISEASE STATE†Year Reference Inducing agent Sample 
Collection 
Method 
Glucose 
Measurement 
Method 
Volume of 
Sample 
[mL] 
Range 
[mM] 
Avg ± std 
[mM] 
Pa-
tients
n Range 
[mM] 
Avg ± std 
[mM] 
Pa-
tients
n
Hagedorn-Jensen 0.22 0.16-0.43 0.34 ± 0.07 12 25     1950 Giardini and  
Roberts50
 
tear gas 
 
pyrex tubes 
 fermentation 
methods 
0.22 0.056-0.28 0.14 ± 0.07 12 25     
1968 Gasset et al.47 spirit of ammonia capillary  enzymatic 0.005-0.020  0.23 ±0.17 28 50  1.53 ± 0.8‡ 26 26
1977 van 
Haeringern  
and Glasius31
2-chloraceto-
phenone 
capillary glucose 
dehydrogenase 
0.020 0.1-1.0* 0.27 10 10 0.5-1.0* 0.76 5 5 
1980 Sen and 
Sarin88
reflex NA glucose oxidase 0.1-0.2   0.20 ± 0.14 50 50  0.92 ± 0.52d 50 50
 0.35 ± 0.06 50 50  0.74 ± 0.16e 25 251982 
 
Gaur et al.70  
 
spirit of ammonia capillary 
 
NA 
 
NA 
      1.20 ± 0.08 50 50
0.18-0.67 0.38± 0.14 35 35     
 0.43± 0.04c+ 25 25  1.05 ± 0.19c 25 25
1983 
 
Sharma et al. 
89
spirit of ammonia 
 
capillary 
 
King and Asatoor 
 
0.05 
 
 0.39± 0.07a+ 25 25  0.90± 0.20a 25 25
1984 Daum and 
Hill82
allium cepa, onion capillary glucose 
dehydrogenase 
0.005 0.3-0.4* 0.35* 3 10     
1987 Desai et al.73 ammonium 
hydroxide 
steel cannula glucose oxidase > 0.2 0-0.28 0.16± 0.11 25 25 0-1.6 0.67± 0.05 40 40
1988 Anonymous90 ammonium 
hydroxide 
NA glucose oxidase 0.13 0.15-0.26 0.21± 0.04 15 15 0.39-1.22 0.75± 0.23 10 10
1995 Das et al.48 spirit of ammonia capillary glucose oxidase NA  0.22± 0.04    1.00 ± 0.22   
0.056-1.00 0.35 ± 0.24 76 76 1.2-1.8 1.58 ± 0.17 52 52
    2.1-3.8 2.68 ± 0.57 44 44
    4.2-5.3 4.67 ± 0.39 16 16
    7.0-7.9 7.44 ± 0.67 8 8 
2003 
 
Chatterjee  
et al.71
spirit of ammonia 
 
dextrostix 
 
glucose oxidase 
 
NA 
 
    9.4-10.2 9.78 ± 0.44 4 4 
2007 Taormina et 
al.60
allium cepa, onion capillary ESI-MS 0.001  0.211 ± 0.008 1 6     
† All disease states reflect diabetes and all normal states reflect normal health, except “a” signifies acute conjunctivitis, “a+” signifies treatment for acute 
conjunctivitis; “c” signifies corneal ulcer, and “c+” signifies treatment for a corneal ulcer. 
‡ Data listed for highest level of glucose observed 
d Chemical diabetes; e Uncontrolled diabetes 
* Estimated from graph 
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The concentration of many analytes is known to vary with tear secretion rate.  Protein and 
calcium concentrations decrease as the flow rate increases, while potassium concentrations 
increase with the flow rate.41  In a 1984 study, Daum and Hill collected 5 μL tear samples every 
20 seconds for 2 minutes after non-diabetic subjects were exposed to raw onion (Allium Cepa) 
vapors for 30 seconds.82  Tear glucose concentration decreased monotonically from 0.3 mmol/L 
(6 mg/dL) before tearing, to 0.1 mmol/L (2 mg/dL) at 2 minutes after exposure.   
Comparison between studies that used chemically stimulated tears is difficult, as different 
lachrymators are used and the precise timing of tear collection is rarely reported.  Some of these 
agents have been shown to cause corneal and conjunctival edema and epithelial erosion or 
ulceration.91  Hence, long term exposure to lachrymators may cause a significant increase in 
glucose concentration as the physical barriers of the ocular surface are compromised.  Use of 
lachrymators is also likely to cause subjects to rub their eyes, which we have anecdotally found 
to correlate with increased tear glucose concentrations in our recent studies.30  
Overall, the average tear glucose concentrations measured in studies of chemically 
stimulated tears fall within the range of tear glucose concentrations measured in non-stimulated 
tears.  Many studies of chemically stimulated tears did not find a general correlation between tear 
and blood glucose for all subjects.50  However, the ability to broadly classify subjects as diabetic 
or non-diabetic through tear glucose measurement, was often demonstrated in these studies, 
especially when postprandial samples were considered.48,71  
4.3.3 Non-stimulated tears 
As more sensitive analytical methods have been developed, investigators have attempted 
to study glucose concentrations in non-stimulated or basal tears (Table 4.3).
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Table 4.3. The Study of Glucose Concentration in Non-Stimulated Tears 
NORMAL DIABETES Year Reference Sample 
Collection 
Method 
Glucose 
Measurement 
Method 
Volume 
of 
Sample 
[mL] 
Range 
[mM] 
Average ± std 
[mM] 
Pa-
tients 
n Range  
[mM] 
Average ± std 
[mM] 
Pa-
tients
n 
1937 Michail and 
Zolog92
capillary NA NA 0 0 8 8     
1937 Michail et al.93  capillary Hagedorn-
Jensen 
NA 0 0 8 8     
1937 Michail et al.21 capillary Hagedorn-
Jensen 
NA 0 0 5 5 1.78-4.89 3.311 ± 0.906 12 12 
1967 Reim et al.86 capillary enzymatic NA  0.13       
1969 Lax80 capillary enzymatic NA  0.206 ± 0.027 43 43     
1982 Daum and Hill28 capillary glucose 
dehydrogenase
0.005 0-3.43 0.42 ± 0.36 12 875     
1983 Mediratia and 
Rohatgi72
capillary glucose 
oxidase 
0.013 0.11-0.33† 0.19 ± 0.04† 30 30 0.67-1.60 1.10 ± 0.26 10 10 
glucose 
dehydrogenase
0.005 0.06-0.90* 0.28a 8 48     1984 Daum and Hill82 capillary 
   0.42b 8 548     
1996 Chen et al.94 capillary glucose 
oxidase 
0.0001-
0.0005 
0.128-0.166 0.139 ± 0.014 6 6     
1997 Jin et al.77  capillary CE-LIF 0.0002-
0.0005 
 0.137 ± 0.013c;  
0.139 ± 0.003d
1 1     
2005 LeBlanc et al.76 capillary HPLC-pulse 
amperometry 
NA     0.0008-0.021* 0.00725 ± 0.005‡ 5e 44 
2006 Lane et al.29  capillary HPLC-pulse 
amperometry 
0.005 0-5.7 0.16 ± 0.03‡ 50 50 0-9.1 0.35 ± 0.04‡ 33 33 
2007 Taormina  
et al.60
capillary ESI-MS 0.001 0.013-0.051 0.032 1 12     
2007 Baca et al.30 capillary ESI-MS 0.001 0.007-0.161 0.028f 25 25     
† Average concentration and range for all age groups 
‡ Mean given 
* Estimated from graph 
a Prolonged closed eyes, b open eyes 
c on column, d precolumn 
e Critically ill patients receiving insulin, where two had a history of diabetes 
f Median given 
Non-stimulated tear samples are generally collected with a capillary by gently touching it 
to the tear film meniscus.  While Daum and Hill trained subjects to collect their own tears 
throughout the day,28,82 most investigators have conducted these investigations by collecting tear 
samples in a clinical setting.   
One of the first large studies of non-stimulated tears measured an average tear glucose 
concentration of 0.42 ± 0.356 mmol/L in 875 tear samples from 12 non-diabetic subjects.28  This 
average tear glucose concentration was somewhat higher than more recent measurements of 
chemically stimulated tears.  While studies using lachrymators could be measuring artificially 
low tear glucose concentrations, it is also possible that some mechanical stimulation was 
involved in the collection of basal tears in this study.  The glucose dehydrogenase method used 
in this study required sample volumes of 5 μL, which would have required sample collection 
times of at least 5 minutes.  Even if mechanical stimulation were avoided during sampling, 
increased evaporation due to the prolonged suppression of blinking could alter the glucose 
concentration.  One of the interesting results of this study was the observation of diurnal 
variations in tear glucose that roughly track changes in blood glucose. 
One of the largest and most recent studies of tear glucose concentration was reported by 
Lane et al. in 2006.29  This study monitored tear glucose concentration in 73 non-diabetic 
subjects and 48 diabetic subjects before and after an oral glucose bolus.  These groups were 
farther divided into fasting and non-fasting groups.  The 5 μL tear samples collected at each time 
point were analyzed with a liquid chromatography-pulsed amperometric detection method.  
Average tear glucose concentration in non-diabetic subjects was 0.16 ± 0.03 mmol/L while 
average tear glucose concentration in diabetic subjects was 0.35 ± 0.04 mmol/L (mean ± 
standard error).  Individual glucose determinations, however, varied from below the limit of 
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detection to over 9.1 mmol/L.  Lane et al. were able to show a modest correlation between 
average tear and blood glucose concentrations at the five time points in the study.  Unfortunately, 
only results averaged over the subject population were given.  Thus there is no indication of how 
well tear and blood glucose concentrations correlate within individual subjects.  The use of 5 μL 
tear samples may have precluded the study of truly non-stimulated tears for the reasons noted 
previously. 
A few recent studies analyzed microliter or submicroliter volumes of tears.30,60,76,77,95  
The previously mentioned study of critically ill patients attempted to assess the feasibility of 
monitoring tear glucose instead of blood glucose in the intensive care unit.76  The investigators 
obtained 44 simultaneous blood and tear samples from 5 sedated subjects who were receiving 
insulin, two of whom had a history of diabetes.  This study measured the lowest average tear 
glucose concentration (7.25 ± 5.47 μmol/L) of any study where glucose was detected in tears.  
Despite a wide range of blood glucose concentrations, the study did not detect a clinically useful 
correlation between these values.  These results in critically ill patients are of little use in 
predicting whether tear fluid analysis can be used to monitor glucose in healthy people.  
However, it is clear that tear glucose monitoring with this method in the ICU is not a feasible 
replacement for blood glucose monitoring. 
A recent study in our laboratory found a median (range) tear glucose concentration of 28 
(7–161) μmol/L or 0.50 (0.13–2.90) mg/dL in 25 fasting subjects.30  The mean (standard 
deviation) tear glucose concentration was 37 ± 37 μmol/L.  We found a highly skewed 
distribution of tear glucose values; tear glucose concentrations were less than 42 μmol/L in 80% 
of subjects.  We found no statistically significant difference between contact lens wearers and 
non-wearers.  Linear regression showed a modest correlation between tear and blood glucose 
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concentrations (R = 0.5).  We compared tear glucose concentrations within subjects over 30 
minutes and did not see any significant trend with time, suggesting that conjunctival irritation 
was minimized or eliminated.  In our study, glucose concentrations were measured using liquid 
chromatography and electrospray ionization mass spectrometry.  Due to the fact that we 
collected only 1 μL tear samples, studied non-diabetic fasting subjects, and observed no evidence 
of conjunctival stimulation, we believe this to be one of the most precise studies of baseline tear 
glucose. 
As described in detail above, there is very little reliable information on whether glucose 
concentrations in unstimulated tears track blood glucose concentrations.  While previous studies 
showed correlations between averaged tear and blood glucose concentrations, there is little direct 
information about the existence of such a correlation within individual subjects.  We recently 
used our mass spectrometry method to investigate the relationship between blood and tear 
glucose concentrations in subjects during a glucose tolerance test (oral administration of 75 
grams of glucose).  Tear samples of 1 μL were collected and analyzed as previously reported, 
and great care was taken to avoid abrasion of the conjunctiva.60  Figure 4.2 shows the blood and 
tear glucose concentrations over time for a non-diabetic subject. 
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 Figure 4.2.  Tear and blood glucose concentrations in a non-diabetic, male subject.  Blood glucose 
concentration doubles by ~70 minutes after glucose ingestion.   
 
Tear glucose concentrations appear to track blood glucose concentrations in this subject 
with a lag time of ~20 minutes.  The tear glucose concentration in the left eye remains elevated 
even after the blood glucose concentration decreases.  While this may be the true physiological 
response for this subject, it could also be explained by an unrecognized irritation of the left 
conjunctiva during the latter half of the experiment (140-160 min).  An essential point is that 
while the blood glucose concentration increases ~2-fold, the left and right eye tear glucose 
concentrations increase ~7-fold.  This demonstrates a complex relationship between tear and 
blood glucose concentrations for this subject. 
Figure 4.3 shows a similar plot of blood and tear glucose concentrations during a glucose 
tolerance test for a diabetic subject.   
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 Figure 4.3.  Tear and blood glucose concentrations in a diabetic, female subject.  Blood glucose 
concentration peaks at ~80 minutes after glucose ingestion with a ~60% increase. 
 
Blood and tear glucose concentrations are clearly higher for the diabetic subject at all 
times.  Prior to glucose ingestion, the blood glucose concentration in this subject was about twice 
as high as for the non-diabetic subject of Figure 4.2.  However, the basal tear glucose 
concentration of the diabetic subject is about ten times higher than for the non-diabetic subject. 
The extraordinary ~5 fold increase in tear glucose concentration in the left eye differs 
completely from the change in the right eye, where (excepting a single point at ~95 minutes) the 
~60% increase in tear glucose concentration is roughly proportional to the increase in blood 
glucose concentration.  It is possible that the dramatic increase in left eye tear glucose 
concentration results from unrecognized conjunctival irritation, causing interstitial glucose to 
leak into the tear fluid.   
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A replicate of the glucose tolerance test shown in Figure 4.2, with the same non-diabetic 
subject, demonstrates the challenge of determining a correlation between tear and blood glucose 
concentration (Figure 4.4). 
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 Figure 4.4.  Tear and blood glucose concentrations in a replicate of the study shown in Figure 4.2.  a) 
The tear glucose concentration scale must be expanded to show the large and abrupt increase in tear 
glucose before glucose intake.  Blood glucose concentration peaks at ~40 minutes after glucose 
ingestion with a ~80% increase. b) Plotting the tear glucose on the same scale as in Figure 4.2 
highlights that the tear glucose concentration appears to track the blood glucose concentration except 
for the early spike in tear glucose concentrations. 
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Identical sampling and tear glucose determination procedures were followed, and the 
same glucose load was given.  Prior to glucose ingestion the blood glucose concentrations are 
similar for both experiments (~105 mg/dL).  Basal tear glucose concentrations at the earliest 
times are also similar (~20 μmol/L).  In contrast to the first study, we see an abrupt increase in 
the tear glucose concentration before glucose intake.  The right eye tear glucose concentration 
increases by ~100 fold, while the left eye tear glucose concentration increases by ~50 fold, 
suggesting non-physiologic transport of glucose into the tear fluid.  The timing and magnitude of 
this spike in tear glucose concentration suggest that the increase may be due to a perturbation 
during sampling.  While we attempted to exclude this possibility, the increased glucose 
concentration in both eyes might suggest that the subject rubbed his eyes after slight conjunctival 
irritation.   
The tear glucose concentrations appear to return to baseline after about 60 minutes.  This 
time scale agrees with the time that Daum and Hill measured for tear glucose to return to 
baseline after the conjunctiva was stimulated by a cotton applicator.82  When the results of the 
replicate study are plotted on the same scale as Figure 4.2, we see that the tear glucose 
concentrations at latter times (after 60 minutes) appear to track changes in the blood glucose 
concentration.  However, the relative tear glucose elevation (~5-fold) in the left eye is much less 
than observed in Figure 4.2, whereas the relative increase in tear glucose concentration in the 
right eye is comparable. 
The bulk of our studies show that before glucose intake, the blood and tear glucose 
concentrations remain relatively constant.  Repeat measurements of tear glucose concentration in 
the presence of a constant blood glucose concentration can be used to define the baseline 
relationship between tear and blood glucose.  After glucose ingestion, the blood and tear glucose 
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concentrations generally increase together, with an apparent 20-30 minute delay between 
increases in blood glucose concentration and in tear glucose concentration. 
In our other studies of tear glucose concentration in subjects undergoing a glucose 
tolerance test, we see only a few instances of the 50-100 fold spikes in tear glucose concentration 
seen in figure 4.  In general, these abrupt changes do not seem to correlate between the different 
eyes of the same subject.  In future studies it would be desirable to use a hyperglycemic clamp96 
to maintain blood glucose at a constant, elevated concentration while tear glucose is measured 
repeatedly.  This would clarify the relationship between tear and blood glucose concentrations in 
the presence of elevated blood glucose concentration.  
While most studies of tear and blood glucose correlation collect and analyze tears from a 
single eye, we measured glucose concentrations in tears from both eyes.  Our preliminary results 
suggest that tear glucose may differ between the left and right eye of a single subject.  While we 
previously showed a general correlation between the tear glucose in the right and left eyes of 
fasting subjects,30 we occasionally observe significant differences in glucose concentration 
between eyes.  Future studies that analyze tear glucose in both eyes could help to better define 
the correlation in tear glucose concentration between left and right eyes.   
While we do not have enough data to specify the precise relationship between tear and 
blood glucose concentrations over time and its variation between subjects, we believe that our 
tear collection method, which specifically attempts to avoid mechanical stimulation of the 
conjunctiva, can answer some of the outstanding questions regarding the utility of tear glucose 
sensing for monitoring or detecting diabetes.  We have shown that we can track changes in tear 
and blood glucose concentrations over time.  However, our results to date indicate that repeated 
tear sampling can effect glucose concentration; it may by extraordinarily difficult to completely 
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and accurately characterize daily tear glucose dynamics with a method that requires the 
collection of a tear sample.  
4.4 IN SITU TEAR GLUCOSE MEASUREMENTS 
There are limited reports of in situ tear glucose determinations using contact lens-based devices.  
March et al. developed and reported the first clinical trial of a contact lens tear glucose sensor.24  
This sensor uses fluorescence to report on the tear glucose concentration using a competitive 
binding mechanism.  As the glucose concentration increases in the modified contact lens, 
quenching groups are displaced and the fluorescent signal increases.  In this study, the absolute 
fluorescent signal was not calibrated to allow the determination of absolute glucose 
concentration.  Rather, fluorescence intensity changes reported on relative changes in tear 
glucose concentrations.  This group also developed a hand held photofluorometer to monitor the 
fluorescent signal.  March et al. reported a glucose tolerance test for five diabetic subjects 
wearing the sensors.  While the fluorescent signal appeared to track the blood glucose 
concentration, the scale had to be changed for each subject in order for the fluorescence signal to 
fit the blood glucose concentration profile.  This study clearly showed that changes in tear and 
blood glucose concentration correlate.  However, this approach would be unable to predict blood 
glucose levels in a patient without extensive calibration of the sensor response and of the 
correlation between tear and blood glucose concentration each time a new contact lens was 
inserted. 
Domschke et al. developed a holographic, glucose-sensitive contact lens and tested it in a 
single subject.25  The wavelength of light diffracted from the contact lens changed as the 
66 
holographic spacing changed in response to glucose binding.  A red-shift in diffracted 
wavelength indicated an increase in glucose concentration.  This sensor motif eliminates the 
challenge of measuring absolute fluorescence intensities.  This sensor also detects relative 
changes in tear glucose concentration.  Domschke et al. did not show a calibration curve for the 
diffracted wavelength dependence on glucose, and only reported the peak diffraction wavelength 
as a function of time.  The peak diffraction wavelength appears to track the increasing blood 
glucose concentration with little or no delay.  These results, while clearly preliminary, indicate 
the potential utility of monitoring tear glucose concentrations in order to determine blood 
glucose concentrations.  Larger studies are needed to evaluate the possibility of long-term tear 
glucose monitoring with these contact lens sensors. 
4.5 THE FUTURE OF TEAR GLUCOSE SENSING 
Any future studies that measure ex vivo tear glucose concentrations must use non-stimulating or 
minimally stimulating collection methods.  As reviewed here, the literature clearly demonstrates 
spuriously high tear glucose determinations when using paper strip collection methods that 
contact the conjunctiva.  While it is clear that measured tear glucose concentration can vary 
throughout the day28 and from eye to eye30 it is still not clear to what extent these variations are 
biological and to what extent they are introduced by the sampling method.  Further studies of 
conjunctiva and lacrimal gland immunohistochemistry along with the cell signaling mechanisms 
behind glucose transport in these tissues may help to better discriminate between biological and 
sampling variations.  
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While several large studies have found evidence for a correlation between averaged tear 
and blood glucose concentrations, the nature of this correlation within individuals is not yet fully 
characterized.  The limited studies of critically ill patients, which showed little blood-tear 
glucose correlation within individuals, contrasts with the clinical studies of contact lens-based 
glucose sensors, which showed significant correlations between blood and tear glucose 
concentrations.   
There is clearly enough evidence of a correlation between tear and blood glucose to 
justify continued efforts to develop contact lens glucose sensors.  Due to the difficulties of 
collecting tear samples without altering the glucose concentration, it may be difficult to predict 
how well these sensors will work on the basis of ex vivo glucose analysis alone.  Only well 
designed in vivo animal studies or further clinical trials of contact lens sensors in humans will be 
able to determine the potential utility of glucose sensing contact lens sensors to help achieve 
glycemic control though non-invasive glucose monitoring.  
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5.0  POLYMERIZED CRYSTALLINE COLLOIDAL ARRAY SENSORS FOR 
POINT-OF-CARE DETECTION OF MYOCARDIAL ISCHEMIA 
Baca JT, Finegold DN, Asher SA. Clinica Chimica Acta 2007; Submitted 
5.1 INTRODUCTION 
Cardiovascular disease is the leading cause of death in the United States, and approximately 1.2 
million Americans will have a coronary attack this year.1  One of the challenges of treating 
Acute Coronary Syndrome (ACS) is the difficulty in rapidly and definitively diagnosing the 
cause of chest pain; only 10% to 15% of patient presenting with chest pain actually have 
myodardial infarction.2  The cost of unnecessary admissions to US hospitals for patients with 
suspected (ACS) is ~12 billion dollars annually.2
Beyond patient history, the electrocardiogram (ECG) is the initial test used to evaluate 
patients with chest pain.3,4  The initial ECG, however is non-diagnostic in 45% of cases of acute 
myocardial infarction5 and appears completely normal in 20% of cases.6  Blood markers such as 
troponins can provide a definitive diagnosis.  However, they do not appear in the blood for 3-4 
hrs after a myocardial infarction, after irreversible cardiac damage has occurred.7  A point-of-
care clinical chemistry test that quickly detects myocardial ischemia would help expedite 
treatment and avoid unnecessary hospital admissions.8
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A decrease in serum binding affinity for Co (II) after ischemia has been described in 
recent reports and this affinity change can potentially be used to detect ischemia before infarction 
occurs.9,10  This change in binding affinity has been termed “Ischemia Modified Albumin” by 
some investigators, although it is possible that albumin modification is not the deterministic 
phenomenon causing changes in Co (II) affinity during ischemia.11  The implication of  Human 
Serum Albumin (HSA) as the origin of the affinity change results because HSA is the most 
abundant metal binding site in human serum; the N-terminus of HSA contains a high-affinity (Ka 
~ 10-15) binding site for Co (II), Cu (II), or Ni (II).12,13   
After an ischemic event, the affinity of human serum for these metals is decreased.14,15  
The observed decrease in cobalt binding capacity is due either to the competitive occupation of 
metal binding sites by Cu (II) or degradation of the site by reactive oxygen species, whose 
formation is catalyzed by copper.16,17  It should be noted that upon an ischemic event, anaerobic 
metabolism produces lactic acid, lowering the local pH and leading to the local release of copper 
and iron complexes.18  Increases in serum nickel levels of  ~20 nmol/L are also observed after 
cardiac ischemia.19   
The decreased cobalt (II) binding affinity disappears 6 hours after transient, induced 
myocardial ischemia,14 suggesting that competitive binding of locally released copper (II) is the 
major factor responsible for decreased cobalt (II) binding.  Studies of commercial albumin 
preparations incubated at physiological temperatures for several weeks suggest that the N-
terminal albumin binding site for transition metals may also be degraded by a metal-independent, 
internal cyclization mechanism.17  This reaction appears to be too slow to account for the rapid 
decrease in cobalt (II) affinity observed after transient myocardial ischemia.  
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A reduction in the cobalt binding capacity of human serum has been measured in several 
clinical trials, and was shown to be useful in ruling out myocardial ischemia, especially when 
combined with other tests.11,20,21  The cobalt binding assay involves complex sample preparation 
and access to a central clinical chemistry laboratory.22  Methods that could detect a change in the 
cobalt (II), nickel (II), or copper (II) binding capacity of human serum or plasma at the bedside 
would improve the utility of this test as an early indicator of ischemia.  A point of care assay that 
does not require specialized instrumentation and sample handling could dramatically improve 
care for millions of patients presenting with ACS.  
Polymerized crystalline colloidal array (PCCA) sensors developed by Asher et al. have 
great potential for point of care sensing applications.23-25  PCCAs contain a highly ordered array 
of colloidal nanoparticles embedded in a hydrogel matrix.26  In low ionic strength solutions, a 
crystalline colloidal array (CCA) forms when highly charged polystyrene spheres self-assemble 
into a face centered cubic lattice.  The spacing between lattice planes can be selected so that the 
CCA Bragg-diffracts light in the visible range.  A PCCA is formed when the CCA is entrapped 
in a hydrogel such as polyacrylamide by photopolymerization.  The lattice spacing and the 
resulting diffracted wavelength becomes a function of hydrogel volume, as swelling or shrinking 
causes a change in the lattice plane spacing.  PCCA sensors can be formed by modifying the 
hydrogel so that a volume change occurs in response to interaction with a specific analyte.  At 
the high ionic strength conditions found in human blood, the most straightforward approach is to 
design the PCCA sensor so that hydrogel crosslinks are formed or broken in response to the 
analyte.  For example, Alexeev et al. recently demonstrated a PCCA sensor that responds to 
glucose when boronic acid groups attached to the PCCA hydrogel bind glucose at two sites of 
the molecule.27
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We present here a PCCA sensor that responds to Ni (II) ions at physiological pH and 
osmolarity.  We show that the sensor responds to Ni (II) in the presence of human plasma, and 
that it can be used to measure the Ni (II) binding capacity of the constituents of human plasma.  
We previously demonstrated PCCA sensors that respond to metal ions such as Co (II), Ni (II), 
and Cu (II) in aqueous solutions at low pH.28  In the work here, we specifically study Ni (II) 
sensing at neutral pH.  Ni (II) is more soluble that Cu (II) at neutral pH and it does not undergo 
the M (II) ? M (III) oxidation that complicates Co ion sensing.28  The PCCA metal sensors 
respond rapidly (within minutes) to changes in Ni (II) concentration, and this method of 
detecting a change in metal binding affinity for plasma is potentially faster than the cobalt 
binding assay.  Since the PCCA metal sensors respond in human plasma, it is not necessary to 
wait for clot formation and to centrifuge the blood sample before analysis.  Red blood cells can 
be rapidly separated from the plasma with size selective membranes or microfluidic 
techniques.29,30  The sensor presented here could potentially shorten the analysis time for changes 
in the metal ion affinity of serum or plasma from ~60 minutes to 5-10 minutes. 
5.2 METHODS 
Monodisperse, highly charged polystyrene nanoparticles were prepared as previously 
described.31  The particle diameter was measured to be 189 ± 9 nm (mean ± SD) by TEM.  After 
dialysis against deionized water and mixing with AG 501-X8 (D) ion-exchange resin (20 to 50 
mesh, mixed bed, Bio-Rad), the system self-assembled into a CCA and exhibited a primary 
diffraction peak at 562 nm at normal incidence.   
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PCCA were formed by photopolymerization of acrylamide (0.10 g, 1.4 mmol, Sigma) 
and N,N′-methylenebisacrylamide (0.002g, 13 µmol, Fluka) dissolved in the CCA (20% w/w 
dispersion of polystyrene latex spheres) following the procedures of Asher et al.28  Before 
polymerization, the colloidal suspension and prepolymer solution was degassed, and the 
evacuation chamber was backfilled with nitrogen.  This solution was injected into a 
polymerization cell (Figure 5.1) that was evacuated in order to remove oxygen.  A gel support 
film containing surface vinyl groups (Bio-rad) used as one face of the polymerization cell, 
covalently attached to the PCCA during photopolymerization (12 min with two 100 watt UV 
lamps, Black Ray).  After polymerization the PCCA was removed from the polymerization cell, 
cut into 10 pieces and stored in deionized water. 
 
Figure 5.1.  Polymerization flow cell (a) consists of a quartz plate with access holes, a parafilm 
spacer, a gel support film, and a solid quartz plate (top to bottom).  The degassed CCA prepolymer 
suspension is injected through tubing connectors (b) and sealed from the environment in order to 
exclude oxygen during polymerization. 
 
Metal ion sensors were made from the PCCA by the method of Asher et al.28  The PCCA 
was first hydrolyzed at room temperature for 2 hours in an aqueous NaOH solution (30 mL, 0.1 
mol/L, Sigma) with 10% v/v N,N,N,N-tetramethylethylenediamine (TEMED; Aldrich).  The 
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hydrolyzed PCCA was then placed in a 30 mL aqueous solution of 5-amino-8-hydroxyquinoline 
(0.14 g, 0.60 mmol, Aldrich) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(EDC; 0.14 g, 0.73 mmol, Pierce) for 2 hours.  After rinsing with deionized water, this coupling 
process was repeated once again. 
NiCl2 stock solutions were prepared by dissolving NiCl2·6H20 (1.189 g, 5.00 mmol, 
Sigma) in either 100 mL of sodium acetate (50 mmol/L, Fisher) buffered saline or 100 mL of N-
(2-Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES; 50 mmol/L, Sigma) buffered 
saline.  The pH was adjusted to 4.2 for the acetate buffered solution and to 7.4 for the HEPES 
buffered solution by addition of 20% NaOH (Sigma).  Solutions with lower Ni (II) concentration 
were prepared by serial dilution. 
Before measuring the response of the PCCA sensors to Ni (II), they were first exposed to 
50 mmol/L NiCl2 solutions for at least 30 minutes, followed by rinsing with the appropriate 
buffer solution.  This was to ensure that the sensors operated in the reversible domain, where the 
diffracted peak wavelength red-shifts with increasing metal ion concentration.28  When a metal 
ion PCCA sensor is first exposed to low concentrations (0 – 10 µmol/L) of divalent ions such as 
Ni (II), Co (II), or Cu (II), there is an initial blue-shift of the peak diffracted wavelength as each 
ion complexes to two 8-hydroxyquinoline moieties to form hydrogel crosslinks.  At higher 
concentrations (10 µmol/L – 50 mmol/L), these crosslinks are broken and the diffracted 
wavelength red-shifts as metal ions are bound by single 8-hydroxyquinoline groups.  The sensing 
response in the red-shifting domain is reversible, whereas the sensor acts as a dosimeter in the 
initial blue-shifting domain.28   
For initial studies of the sensor response, the analyte solutions were exchanged before 
each diffraction peak measurement in order to vary the metal ion concentration.  We maintained 
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a volume ratio of approximately 1000:1 for the solution volume to the PCCA sensor volume.  
We measured replicates of the peak diffraction wavelength of a PCCA sensor at different Ni (II) 
concentrations in order to determine the standard deviation of the measurement.  
Standard addition studies were conducted by adding small volumes (50-500 µL) of 
concentrated Ni (II) solution to the large (30-50 mL) buffer reservoir bathing the sensor.  The 
diffraction of the PCCA was monitored using a 6 around 1 reflectance probe and a fiber-optic 
diode spectrometer with a tungsten halogen light source (Ocean Optics). 
For PCCA dehydration experiments, the sensor was left in a HEPES buffered saline 
solution containing a total of ~1.5 mmol NiCl2 and allowed to dehydrate by exposure to room air 
over 3 days.  The sensors were rehydrated by adding deionized water to the dish, and rinsed with 
HEPES buffer prior to additional sensing experiments. 
For the Ni (II) binding experiments, 10 mL of human plasma was added to 20 mL of 
HEPES buffered saline solutions with known Ni (II) concentrations.  This human plasma was 
separated from a pooled, heparinized whole blood sample (Bioreclamation) by centrifugation.  
The sodium heparin had a molecular weight of ~12 kDa and was present at a concentration of 15 
USP units per 1 ml of whole blood. 
5.3 RESULTS 
Figure 5.2 shows several sequential measurements of the peak diffracted wavelength for a PCCA 
sensor as the Ni (II) concentration is varied.  Based on the variance of these measurements, we 
calculate a maximum standard deviation of 0.6 nm for the peak diffracted wavelength at the 
different Ni (II) concentrations and a standard deviation of 0.2 nm at 0.75 mmol/L.  The peak 
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diffracted wavelength shift is roughly linear over Ni (II) concentrations between 0.2 mmol/L and 
1.0 mmol/L (Figure 5.3a), which is the relevant pathophysiologic range for monitoring changes 
in plasma metal binding capacity.  We can use the slope of the response curve (8.6 
nm/(mmol/L)) to express the standard deviation in terms of Ni (II) concentration (0.07 mmol/L 
at 7.5 mmol/L and 0.02 mmol/L at 0.75 mmol/L). 
 
Figure 5.2.  Time dependence of peak diffracted wavelength of the PCCA sensor upon alteration of 
Ni (II) concentration for 5 consecutive replicates.  Solutions contained 50 mmol/L HEPES buffer and 
150 mmol/L NaCl.  Each curve represents a different replicate cycle.  Vertical lines indicate times 
when the analyte solution was replaced.  Added solutions contained 0.75 mmol/L NiCl2 at 0 minutes 
and 7.5 mmol/L NiCl2 at 30 minutes.  At 60, 90, and 120 minutes, the solution was replaced with 
HEPES buffered saline.  The peak diffracted wavelength was 439.5 ± 0.5 nm at 0 mmol/L NiCl2, 
451.7 ± 0.2 nm at 0.75 mmol/L, and 476.5 ± 0.6 at 7.5 mmol/L (average ± SD).  This yields an overall 
standard deviation of ± 0.5 nm. 
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Figure 5.3 shows the response of a PCCA Ni (II) sensor at pH 4.2, and pH 7.4.  The 
response profiles are very similar, except that diffraction is blue-shifted by approximately 10 nm 
at the higher pH.   
 
Figure 5.3.  a) The dependence of peak diffracted wavelength on NiCl2 concentration and pH: 
pH=4.2 (□) and pH=7.4 (◊).  At pH=4.2, solutions contain 50 mmol/L sodium acetate and 150 mmol/L 
NaCl.  At pH=7.4, solutions contain 50 mmol/L HEPES buffer and 150 mmol/L NaCl. The inset 
shows the linear response range between 0.2 mmol/L and 1.0 mmol/L Ni (II).  b) Observed 
reflectance diffraction spectra for the pH=7.4 curve points. 
 
84 
Figure 5.4 shows the effects of dehydrating the PCCA sensor.  The response profiles 
before and after dehydration are very similar, except that peak diffraction red-shifts and the 
sensor sensitivity decreases.  For example, the wavelength shift in response to 1 mmol/L Ni (II) 
was diminished from 12.9 nm to 8.8 nm.  The intense Bragg diffraction peak that is indicative of 
PCCA ordering is recovered after rehydration (Figure 5.4 inset).  
 
Figure 5.4.  Dependence of peak diffracted wavelength on NiCl2 concentration before (◊) and after 
(□) dehydration.  The sensitivity of the PCCA sensor is decreased after rehydration as the peak 
wavelength diffraction shift between 0 to 1 mmol/L NiCl2 decreases from 12.9 nm before dehydration 
to 8.8 nm after rehydration. The inset shows the diffraction spectrum at 0.98 mmol/L before and 
after dehydration.  The peak diffracted wavelength shifts 2 nm from λ=453.5 nm (before 
dehydration) to λ=455.5 nm (after rehydration).  The PCCA sensor was dehydrated and rehydrated 
in situ. Thus, the diffraction spectra are from identical spots of the sensor. 
 
Addition of human plasma to a nickel-free buffer solution surrounding the sensor shifts 
the peak diffracted wavelength by ~2 nm (Figure 5.5).  Initially, there is a small, rapid blue shift, 
followed by a much smaller and more gradual red-shift.  After the removal of plasma, and 
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rinsing with buffer, the peak diffracted wavelength returns to the original value.  We observe no 
evidence of coagulation or clot formation during these experiments. 
 
Figure 5.5.  (a): Response of PCCA sensor to human plasma in the absence of NiCl2.  Plasma was 
added to the analyte solution (50 mmol/L HEPES and 150 mmol/L NaCl) at 21 min to form a 2:1 
(buffer:plasma) solution.  After rinsing with HEPES buffer, the peak diffracted wavelength returns 
to its original value. 
 
Figure 5.6a shows the effect of adding 10 mL of human plasma to a PCCA sensor 
equilibrated in 20 mL of a 0.75 mmol/L NiCl2 solution containing 50 mmol/L HEPES buffer and 
150 mmol/L NaCl.  There is a rapid 12.4 nm blue-shift, which is much larger than in the absence 
of Ni (II).  Figure 5.6b shows the effect of adding the same volume of buffer rather than plasma.  
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Accounting for the osmotic effects of plasma addition, we find that the human plasma binds 1.0 
mmol Ni (II) per L of human plasma (see Discussion below). 
 
Figure 5.6.  (a) Response of PCCA sensor to human plasma addition in the presence of NiCl2. The 
sensor initially red-shifted in response to 0.74 mmol/L aqueous NiCl2 in 50 mmol/L HEPES buffer 
and 150 mmol/L NaCl.  Addition of human plasma at 346 minutes caused a blue-shift of 12.4 nm.  (b) 
Response of PCCA sensor to HEPES buffer addition in the presence of NiCl2.  Addition of HEPES 
buffer at 199 min caused a blue-shift of 0.7 nm, due to dilution of NiCl2 to a concentration of 0.49 
mmol/L.   
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We observe a sustained and linear red-shift of 0.5 nm/hr after the addition of plasma and 
Ni (II) (not shown).  This small red shift is within the error of the measurement for a single 
concentration determination lasting 10-20 minutes. 
5.4 DISCUSSION 
Based on the standard deviation of 0.02 mmol/L (at a Ni (II) concentration of 0.75), we can 
expect to reliably detect changes in plasma binding capacity of 60 μmol/L.  PCCA metal sensors 
were previously studied at pH 4.2.28  However, the affinity of the N-terminal metal binding site 
in HSA for Co (II) markedly decreases at pH values below 6.2.15  The response profiles at pH 4.2 
and pH 7.4 are very similar, except that diffraction is blue-shifted by approximately 10 nm at the 
higher pH (Figure 5.3).  This difference is likely due to a slightly lower affinity of 8-
hydroxyquinolines for Ni (II) at lower pH.32   
The ability to maintain PCCA sensors in dry storage before use would greatly aid the 
development of these sensors for practical clinical applications.  However, until now, there has 
been no demonstration that PCCA sensors can be reversibly dehydrated and rehydrated. Figure 
5.4 shows that our Ni (II) PCCA sensor can be reversibly dehydrated.  We believe this to be the 
first report of a PCCA sensor that can be reversibly dehydrated and rehydrated.  (Sanford Asher, 
Michelle Muscatello and Lee Stunja in our lab are studying the reversible dehydration of PCCA 
glucose sensors, and are in the process of preparing a manuscript on this topic.)  Unconstrained 
PCCA sensors generally become brittle during the drying process and often crack.  Attachment 
to a gel support film seems to force the sensor to dry more uniformly, which prevents formation 
of cracks.  Polyacrylamide electrophoresis gels are often dried in the presence of concentrated, 
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low molecular weight stabilizers such as glycerol, urea, or ethanol33,34; the presence of the 
HEPES buffer during drying likely acts in a manner similar to other low molecular weight 
stabilizers, preventing the irreversible collapse of polyacrylamide chains.   
While the response of Pb (II), creatinine, and ammonia PCCA sensors in human and 
bovine serum has been studied previously,23,24,35 the response of PCCA sensors to human plasma 
has not been investigated.  As shown in Figure 5.5, the sensor exhibits a small and rapid initial 
blue-shift followed by a smaller and more gradual red-shift.  This two-phase response is typical 
of hydrogels placed in a hypertonic solution evolving to osmotic equilibrium.36  The addition of 
plasma initially creates hypertonic conditions outside of the hydrogel and water flows out of the 
hydrogel to equalize the osmotic pressure.  At longer time scales, plasma proteins such as 
albumin diffuse into the hydrogel, diminishing the osmotic pressure.  Previous work suggests 
that the diffusive permeability of albumin in a polyacrylamide hydrogel such as those studied 
here is approximately 10-8 cm2s-1.37  This means that on the time scale of the experiment (20 
minutes), the average albumin molecule will diffuse only about 50 μm into the hydrogel.  For 
this reason, the red-shifting back towards the baseline wavelength is slow.   
The large PCCA sensor blue shift in response to plasma, when Ni (II) is present, cannot 
be explained by osmotic effects of plasma or by dilution effects. Figure 5.6b shows the effect of 
adding the same volume of buffer rather than plasma.  We hypothesize that the components 
proteins of human plasma, especially albumin, sequester Ni (II), leading to a blue-shift in the 
diffracted wavelength as the effective concentration of Ni (II) decreases.  Comparing the 
diffracted wavelength shifts for our sensor after plasma addition with the Ni (II) calibration curve 
allows us calculate the concentration of Ni (II) bound.  Accounting for the osmotic effects of 
plasma addition described above, we find that the human plasma preparation binds 1.0 mmol Ni 
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(II) per L of human plasma.  The reference interval for human serum albumin in adults is 35-52 
g/L (0.53-0.78 mmol/L).  Hence, other species in the plasma preparation must also have a 
significant affinity for Ni (II).  Nickeloplasmin38 and histidine39 have been identified as the major 
species besides serum albumin that bind nickel in human plasma.  Proteins involved in the 
clotting cascade40 (factor VIII) and the alternative complement pathway41 (C-3 convertase) are 
also known to bind Ni (II).  While such species will decrease the total free Ni (II) concentration 
measured by our sensors, unless their Ni (II) binding affinity changes due to ischemia, they will 
not impact the measurement of ischemia induced changes in plasma Ni (II) binding.    
As noted above, we observe a small, linear red shift over time after the addition of plasma 
and Ni (II).  One plausible explanation is that albumin or other plasma proteins are reacting with 
and/or binding to the hydrogel.  Binding of these proteins may alter the free energy of mixing of 
the hydrogel.  This small red shift is within the error of the measurement for a single 
concentration determination lasting 10-20 minutes.  However, it would become significant 
during longer experiments, complicating standard addition experiments, where several 
measurements must be made after the addition of plasma.  
We demonstrate here the ability to measure a change in the nickel concentration in the 
presence of human plasma as it is sequestered by the constituents of plasma.  This is the required 
first step in developing a PCCA sensor for the rapid detection of myocardial ischemia.  Future 
studies will be needed to establish reference intervals and to standardize this assay.   
Previous studies suggest that it is possible to make polyacrylamide PCCA metal sensors 
which undergo greater wavelength shifts in response to Ni (II), Co (II), or Cu(II).28  This is 
generally accomplished by modifying the hydrogel volume fraction and initial cross link density.  
If the sensors showed large wavelength shifts between 0 and 1 mmol/L a simple visual 
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inspection of the sensor could be used to determine the test result.  However, since some end 
users may be color blind, and for documentation purposes, it may be preferable to use a handheld 
spectrometer to determine the peak diffracted wavelength. 
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6.0  SYNTHESIS OF UNIFORM PCCA SENSORS ON SOLID SUPPORT 
One of the difficulties in fabricating and testing PCCA sensors is that they must be immobilized 
against a flat surface in order to ensure that diffraction is monitored along the normal direction.  
Previous solutions to this problem often rely on the fact that during some stage of the fabrication 
process, PCCA sensors often become “extremely sticky”.1  This allows the sensor to adhere to a 
polystyrene Petri dish when it touches the surface.  This process can lead to wrinkles in the 
hydrogel surface, potentially complicating diffraction measurements.  It also makes removal of 
the PCCA sensor from the Petri dish either difficult or impossible.  The Asher group has 
previously reported attachment of a PCCA sensor for lead to a plastic film in order to form an 
optrode.2  This approach, however, has not been widely applied to other PCCA sensors and is not 
described in detail in the literature. 
Polyacrylamide gels are often used in biochemical studies for the separation of proteins 
or nucleic acids.3  These hydrogels can be covalently bound to a solid support such as GelBond 
PAG film (Bio-Rad) during photopolyermization.  This type of solid support generally consists 
of a transparent plastic film coated with a resin that contains vinyl groups, which can co-
polymerize with the acrylamide gel.4   
We investigated the formation of a PCCA while the CCA precursor was in contact with a 
gel support film in order to covalently attach the PCCA to this gel support film.  We successfully 
attached polyacrylamide PCCAs to GelBond gel support films, and have described the use of 
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these sensors in a paper submitted to Clinica Chimica Acta (Chapter 5).  The present chapter 
expands on the synthesis of uniform PCCA sensors attached to a solid support. 
6.1 EXPERIMENTAL METHODS 
 As described in section 5.2, PCCA were formed by photopolymerization of acrylamide 
(0.10 g, 1.4 mmol, Sigma) and N,N′-methylenebisacrylamide (0.002g, 13 µmol, Fluka) dissolved 
in the CCA (20% w/w dispersion of polystyrene latex spheres) following the procedures of 
Asher et al.1  Before polymerization, the colloidal suspension and prepolymer solution was 
degassed and the evacuation chamber was backfilled with nitrogen.  This solution was then 
immediately injected into a polymerization cell that had been evacuated in order to remove 
oxygen (Figure 6.1).   
 
Figure 6.1. Photograph of the polymerization cell used to fabricate a PCCA attached to a gel support 
film.  This picture was taken immediately after injection of the colloidal suspension, before 
polymerization.  A schematic drawing of this polymerization cell appears in Figure 5.1. 
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The polymerization cell consists of a quartz plate on one side and a gel support film, 
which is supported by another quartz plate on the other side.  The top quartz plate and the gel 
support film are separated by a parafilm spacer.  In contrast to previous polymerization cells 
employed by the Asher group, the colloidal suspension was injected into the polymerization cell 
through plastic tubing connectors in order to help exclude oxygen diffusion into the cell during 
polymerization.  In some control experiments, one side of the polymerization cell was left 
exposed to the atmosphere during polymerization. 
The gel support film contains surface vinyl groups, which copolymerize with the PCCA 
during photopolymerization (12 min with two 100 watt UV lamps, Black Ray).  After 
polymerization, the PCCA attached to the support film is easily removed from the 
polymerization cell, and does not adhere to the top quartz plate.  The PCCA and the underlying 
support film can then be cut into several pieces.  If a margin or “tab” is left around the PCCA 
when cutting the support, the PCCA can be easily manipulated and transferred without 
contacting it directly. 
6.2 RESULTS AND DISCUSSION 
Careful deoxygenation of the colloidal suspension and the polymerization cell is crucial to 
forming a uniform PCCA.  If the suspension is not evacuated, the polymerized PCCA will often 
detach from the gel support film.  If one side of the polymerization cell is left open to the 
atmosphere during photopolymerization, the resulting PCCA is not uniform (Figure 6.2). 
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Figure 6.2.  Two PCCAs attached to gel support films, and polymerized under different conditions.  
These PCCAs have been removed from the polymerization cell and thoroughly rinsed with deionized 
water.  The colloidal suspensions in both cases were degassed before injection into the polymerization 
cell.  The PCCAs were photographed immediately after polymerization, before any modification of 
the acrylamide hydrogel.  a) When one side of the polymerization cell is left open to the environment, 
the diffracted wavelength is clearly not uniform.  b) When the colloidal suspension is injected 
through plastic tubing connectors and the polymerization cell is sealed from the environment during 
polymerization, the wavelength diffracted by the PCCA is much more uniform. 
 
For the PCCA shown in Figure 6.2a, the colloidal suspension was injected into the 
polymerization cell from left to right, and the right side remained exposed to the atmosphere 
during photopolymerization.  The diffracted color on the right side of the PCCA is red-shifted 
relative to the left side.  This suggests that the crosslink density of the hydrogel decreases 
moving from the left to right across the pictured PCCA.  This change in cross link density is 
likely due to the presence of an oxygen gradient inside the cell during photopolymerization.   
In contrast, the PCCA shown in Figure 6.2b is fairly uniform in its diffracted wavelength.  
The exclusion of oxygen from the polymerization cell throughout the polymerization process 
appears to aid in the fabrication of a uniform PCCA attached to a gel support film.   
PCCAs formed in the absence of a gel support film also appear to be sensitive to oxygen 
gradients during polymerization (Figure 6.3).   
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Figure 6.3. Two PCCAs that were polymerized in the absence of a gel support film.  These PCCAs 
have been removed from the polymerization cell and thoroughly rinsed with deionized water.  In 
both cases, the colloidal suspension was degassed before injection into the polymerization cell, and 
one side was left open to the atmosphere during polymerization. a) The colloidal suspension was 
exposed to the atmosphere for several minutes after degassing, before injection into the 
polymerization cell. b) The colloidal suspension was injected into the polymerization cell immediately 
after degassing. 
 
These PCCAs in Figure 6.3 were formed using polymerization cells consisting of two 
quartz plates and a parafilm spacer; the gel support film was omitted.  As in Figure 6.2a, one 
access hole of the cell was left open to the environment during polymerization.  When the 
colloidal suspension is allowed to equilibrate with the atmosphere before injection into the 
polymerization cell, large gradients in diffracted wavelength are not observed (Figure 6.3a).  
However, when the colloidal suspension is immediately injected into the polymerization cell, the 
diffracted wavelength gradient is similar to that observed in Figure 6.2a.  The colloidal 
suspension was injected from left to right for the PCCA in Figure 6.3b, and the right side was 
exposed to the environment during polymerization.  Similar concentrations of acrylamide and 
methylenebisacrylamide were present in all colloidal suspensions prior to injection.  However, 
the light diffracted from this PCCA in Figure 6.3b (green to red) is red-shifted relative to the 
light diffracted from the PCCA in Figure 6.2a (blue to yellow).  The hydrogel may be 
particularly constrained when covalently attached to a gel support film on one side, and hence 
swell to a lesser extent in water. 
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6.3 CONCLUSIONS 
We have demonstrated the synthesis of uniform PCCAs on a gel support film.  This allows for 
easier manipulation and testing of PCCA sensors.  PCCAs attached to gel support films may then 
be further modified to sense a variety of analytes including metal ions,1,5 creatinine,6 ammonia,7 
glucose,8 and organophosphate nerve agents.9  The method developed here can be employed in 
developing and testing future PCCA sensors.   
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7.0  FUTURE WORK 
Our investigations have contributed to the development of point-of-care sensors for use in 
treating diabetes and detecting myocardial ischemia.  Further work is needed to complete the 
development of these sensors for clinical use.  In this section, we outline the necessary work. 
7.1 FUTURE STUDIES OF TEAR GLUCOSE 
In Chapter 3, we demonstrated the utility of the tear glucose analysis method developed in 
Chapter 2 for measuring tear glucose concentration in fasting non-diabetic subjects.  Using a 
sampling method designed to minimize irritation of the eye, we demonstrated that tear glucose 
concentration is significantly lower than previously believed.  The next step will use this method 
in further determinations of tear glucose concentration in diabetic subjects, and in non-diabetic 
subjects with elevated blood glucose concentrations.  We also plan in situ tests of the glucose 
sensors developed by Alexeev et al. and Ben-Moshe et al.1, 2
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7.1.1 Ex vivo studies of tear glucose concentration 
While we characterized the basal tear glucose concentration in non-diabetic subjects, it remains 
unclear precisely how diabetes may affect tear glucose concentrations.  The microvasculature, 
especially in the retina, kidneys, and extremities, is often damaged due to elevated blood glucose 
levels in diabetic patients.3  As described in Chapter 4, previous studies of tear glucose 
concentration in diabetic subjects have generally used tear collection techniques that may irritate 
the cornea and artificially elevate the tear glucose concentration.  Further studies, using a non-
stimulating collection method, are needed to characterize tear glucose concentrations in diabetic 
subjects.  An increased tear glucose concentration in diabetic subjects could be due to an 
increased blood glucose concentration, or it could be due, in part, to an alteration of glucose 
transport in tears caused by the sequelae of diabetes. 
7.1.1.1 Tear Glucose Concentration in Fasting Diabetic Subjects 
We plan to study tear glucose concentration in diabetic subjects as well as in non-diabetic 
subjects with elevated blood glucose levels.  Our previous work has shown that tear glucose 
concentrations can vary considerably, even within a fasting subject.4  The standard deviation in 
our measurement of tear glucose for an individual is approximately half of the average tear 
glucose concentration for that individual.4  We have also shown that tear glucose can increase 
several fold after glucose ingestion.  For this reason, we will initially study tear glucose 
concentration in subjects where the blood glucose concentration is constant.  We will collect tear 
glucose from diabetic subjects who have fasted overnight.  While blood glucose in theses 
subjects may be elevated, it should remain relatively constant over a 30 minute interval.  We will 
collect three tear samples from each eye at intervals of ~15 minutes, following the same 
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procedures as in our study of fasting, non-diabetic subjects.4  This will allow us to determine the 
variance in tear glucose for diabetic subjects, and will help determine the relationship between 
tear and blood glucose in these subjects.   
We previously attempted to measure tear glucose concentrations in diabetic subjects who 
were visiting the University of Pittsburgh Medical Center Diabetes Clinic.  While this was an 
excellent location to recruit diabetic subjects, it was not possible to collect more than a single 
tear sample from each eye due to the time and space constraints of this busy clinic.  Additionally, 
the fasting state of subjects was not always controlled.  While some subjects were specifically 
undergoing phlebotomy for the measurement of fasting blood glucose concentration, others were 
having blood tests that did not require prior fasting.  The tear samples from this study were 
analyzed using an early version of the mass spectrometry method that did not employ a column 
for the separation of glucose.  We later determined that we could not accurately quantify glucose 
concentrations below ~100 μmol/L using the initial mass spectrometry method.  Considering the 
difficulties of collecting several tear samples in a busy diabetes clinic, we plan to conduct future 
studies of subjects with diabetes in a research setting, where the fasting state can be controlled 
and where we will have time to collect at least three tear samples from each eye. 
7.1.1.2 Tear Glucose Concentration in Hyperglycemic Non-Diabetic Subjects 
 In order to understand how elevated blood glucose concentrations affect tear glucose 
concentrations in the absence of diabetes, we will also study non-diabetic subjects with elevated 
blood glucose concentrations.  We will attain constant, elevated blood glucose concentrations for 
these subjects by using a hyperglycemic clamp.5  This procedure uses intravenous injection of 
glucose along with frequent monitoring of blood glucose concentration to maintain constant, 
elevated glucose concentrations.  The elevated blood glucose concentrations safely attainable 
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with a hyperglycemic clamp in non-diabetic subjects will not be as high as the blood glucose 
concentrations frequently seen in diabetic subjects.  However, even a modest increase in blood 
glucose concentration (~50%) will allow us to determine basal tear glucose concentrations in 
non-diabetic subjects over a much greater glycemic range.  Again, we will follow the tear 
collection and analysis methods described in Chapters 2 and 3 so that we can compare our future 
and prior results. 
 We may need to study fairly large populations in order to obtain statistically significant 
measurements of tear glucose concentration.  We cannot precisely predict the standard deviation 
of measured tear glucose concentration for hyperglycemic subjects.  Our initial assumption will 
be that the relationship between the standard deviation and the average tear glucose 
concentration is the same for all subjects.  An initial, pilot study of ~10 fasting diabetic subjects 
and ~10 non-diabetic subjects undergoing a hyperglycemic clamp will be done to help calculate 
the size of the population needed to obtain statistically significant results. 
7.1.2 In Situ Studies of Tear Glucose Concentration 
The most definitive way to assess the utility of monitoring tear glucose concentration with 
contact lens-based sensors is to test these sensors clinically.  While studies that remove tear fluid 
from the eye help to establish the general range of tear glucose concentrations in tear fluid, they 
cannot predict how well an in situ tear glucose sensor will predict blood glucose concentration.  
Initial studies should be done in animals in order to characterize the biocompatibility of these 
sensors. 
PCCA sensors have not been previously used in living animals or humans.  The 
biocompatibility tests needed to demonstrate the safety of theses materials are well established 
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and are described in the ISO (International Organization for Standardization) standard ISO-
10993-1:2003, (Biological evaluation of medical devices Part 1: Evaluation and testing).6  (Table 
7.1.) 
Table 7.1. Biocompatibility Tests and ISO references 
Biocompatibility Test Test method ISO reference 
cytotoxicity 
Agar Diffusion: determines 
mammalian cytotoxic potential of 
leachable components in the PCCA 
sensor. 
ISO 10993-5:1999 (Biological 
evaluation of medical devices 
Part 5: Tests for in vitro 
cytotoxicity) 
skin irritation 
Monitors erythema and edema in 
rabbit skin after prolonged contact 
with the PCCA sensor. 
ISO 10993-10:2002 (Biological 
evaluation of medical devices 
Part 10) 
ocular irritation 
Quantifies ocular lesions in rabbits 
in response to contact with the 
PCCA sensor. 
ISO 10993-10:2002 (E) Annex B 
(Ocular Irritation Test) 
contact lens biocompatibility 
Monitors response of rabbit eyes 
using a standard scoring system 
under standard contact lens wear 
and care conditions. 
ISO 9394:1998 (Ophthalmic 
optics – Contact lenses and 
contact lens care products – 
Determination of biocompatibility 
by ocular study with rabbit eyes) 
 
This ISO standard describes what tests are needed to assess the biocompatibility of a 
medical device, and the above table was constructed to conform to these guidelines.  These 
studies should be completed in the order listed, as any adverse result will obviate the need for 
further studies.  While these studies can be performed in any lab with the proper certifications, it 
is often more expedient to have these tests done by a facility that specializes in biocompatibility 
testing. 
Assuming that the results of initial biocompatibility tests are favorable, we will carry out 
further in vivo tests of contact lens-based PCCA glucose sensors.  Because contact lenses are 
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frequently tested in rabbits, and because there are well established models of diabetes in rabbits, 
initial in vivo testing will be done in these animals.  The normal range of blood glucose 
concentration is similar in rabbits and in humans.  Also, the blood glucose concentration in 
rabbits can be easily manipulated by glucose or insulin injections.  We will monitor the 
diffracted wavelength of light from a PCCA glucose senor while it is in the rabbit eye.  We will 
also measure blood glucose concentration in the rabbit to determine the correlation between 
diffracted wavelength and blood glucose concentration.  Rabbits will be particularly useful for 
studying the extreme ranges of hyperglycemia and hypoglycemia that may be dangerous to 
produce experimentally in humans.   
Finally, these sensors will need to be tested in human subjects.  The lenses should first be 
studied in habituated contact lenses wearers.  Clinical protocols such as the ones described in the 
previous section will be used to study the sensors under a variety of blood glucose conditions.  
The diffracted wavelength of light will be monitored during fasting and during a glucose 
tolerance test.  Previous studies of in situ contact lenses have demonstrated the utility of glucose 
tolerance tests assessing the ability of the sensor to predict blood glucose concentrations.7, 8  
7.2 FUTURE STUDIES OF POINT-OF-CARE SENSORS FOR MYOCARDIAL 
ISCHEMIA 
We showed in Chapter 5 that PCCA sensors can report on the metal binding affinity of plasma.  
In order to further develop this sensor, we will need to optimize its response over the relevant 
analytical range and conduct clinical trials with blood samples from ischemic and control 
subjects.   
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7.2.1 Optimization of PCCA sensors for Nickel 
There are several approaches that could potentially increase the response of the PCCA sensors to 
changes in the metal binding affinity of plasma.  Decreasing polymer crosslink density is one 
approach to increasing the sensitivity of polyacrylamide PCCA sensors.  The sensors described 
in Chapter 5 have a crosslink to monomer ratio of 1:100.  Decreasing this ratio will allow for 
greater swelling of the hydrogel so that sensor response to Ni2+ concentrations between 0 and 1 
mmol/L covers a larger portion of the visible spectrum.   
We will also attempt to attach more 5-amino-8-hydroxyquinoline groups to the hydrogel.  
This can be accomplished by increasing the hydrolysis of amides in the hydrogel and repeating 
the EDC coupling step, which attaches 5-amino-8-hydroxyquinoline to carboxylate groups.  
While it is difficult to quantify the attachment of the 5-amino-8-hydroxyquinoline groups to the 
PCCAs, we can monitor attachment of these moieties to a colloid-free polyacrylamide hydrogel 
as previously demonstrated.9  
We have shown that the current sensors can distinguish changes in free Ni2+ 
concentration as low as 60 μmol/L, and this is likely sufficient to sense clinically significant 
changes in the metal binding affinity of plasma.10  However this change in Ni2+ concentration 
corresponds to a peak diffracted wavelength shift of 0.6 nm.  To improve the response of the 
PCCA sensors, we should also investigate attaching chelating agents with a higher affinity for 
Ni2+ ions.   Figure 7.1 shows the response of these PCCA metal sensors to a wide range of Cu2+ 
ion concentrations. 
107 
PCCA Response to Cu2+ Titration
420
440
460
480
500
520
540
560
1.0E-10 1.0E-08 1.0E-06 1.0E-04 1.0E-02 1.0E+00
Concentration Cu Added / mol/L
Pe
ak
 D
iff
ra
ct
ed
 W
av
el
en
gt
h 
/ n
m
 
Figure 7.1. Response of a PCCA sensor for metal ions to low concentrations of Cu2+.  The sensor 
initially blue-shifts as additional hydrogel crosslinks are formed when two 8-hydroxyquinoline 
ligands bind each Cu2+ ion.  The sensor acts as a dosimeter in this domain.  At metal ion 
concentrations greater than ~50 μmol/L, the sensor red-shifts with increasing Cu2+ concentration as 
crosslinks are broken when Cu2+ ions are bound by a single 8-hydroxyquinoline.  The sensor 
response in this range is reversible.  An identical response is expected for Ni2+. 
 
We currently use the PCCA sensors in the domain where increasing metal ion 
concentration causes a red-shift in the peak diffracted wavelength.  In this range, increasing the 
density of metal chelating groups on the hydrogel and decreasing the bisacrylamide crosslink 
density should increase the range diffracted wavelengths observed in this reversible response 
domain.  Using chelating agents with a higher association constant should increase the slope of 
the sensor response in the relevant analytical range of metal ion concentrations (10-5 - 10-3 
mol/L). 
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7.2.2 Testing of PCCA metal sensors with ischemic plasma samples 
While the PCCA metal ion sensors may be optimized for larger shifts in diffracted wavelength 
over the relevant (0.1-1.0 mmol/L) analytical range, their response is sufficient to begin testing 
clinical plasma samples.  We have submitted a proposal to the institutional review board at the 
University of Pittsburgh to collect and study blood samples from patients who are undergoing a 
clinically indicated cardiac stress test with myocardial perfusion imaging.  Many of the patients 
undergoing such a test are expected to experience cardiac ischemia during exercise, and this 
ischemia will be determined by imaging with a radioactive contrast agent.  We have proposed to 
collect two blood samples from patients who are undergoing this test in the course of their 
routine medical care.  One sample will be collected before the test begins, and the second will be 
collected 15-20 minutes after maximum exertion.  This will allow us to study plasma samples 
from subjects in the presence and absence of myocardial ischemia.  While not all subjects will 
experience myocardial ischemia during the stress test, the results of the myocardial perfusion 
imaging will indicate which subjects experienced significant ischemia.   
We will use the sensors as described in Chapter 5 to determine the change in the metal 
binding affinity of plasma from these subjects in the presence of ischemia.  We will use two 
pieces of the same PCCA sensor to test the two plasma samples from each subject.  This will 
ensure that the exact same sensor composition is present for each pair of plasma samples.  After 
testing the samples, we will review the results of the myocardial perfusion tests to determine 
whether decreased myocardial perfusion correlates with a decrease in the metal binding affinity 
of plasma as determined by our sensors.  We initially plan to study blood samples from about 50 
subjects, 25% of whom are expected to show signs of myocardial ischemia during the stress test.  
This pilot study will aid in planning future clinical studies. 
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Finally, a large clinical study using the optimized sensor would be needed to confirm the 
utility of these PCCA sensors for rapidly detecting myocardial ischemia.  This study should be 
performed in a clinical setting similar to where the sensors would potentially be used.  This 
would likely be in an emergency medicine department.  Other tests for myocardial ischemia, 
such as the cobalt binding assay, or tests for myocardial infarction, such as immunoassays of 
cardiac troponins, would be done simultaneously.  This would help to determine the ability of the 
PCCA sensors to detect myocardial ischemia and to predict myocardial infarction in comparison 
with current tests.   
7.3 CONCLUSION 
The work described in the first six chapters contributes significantly to the development of point-
of-care sensors for the management of diabetes and the rapid detection of myocardial ischemia.  
The future studies outlined above will complete the development of these sensors, and move 
them towards practical use in the diagnosis and management of two of the deadliest diseases we 
currently face.  Non-invasive tear glucose sensors have the potential to improve glycemic control 
in patients with diabetes, and delay or prevent the complications of this disease. Sensors for the 
rapid detection of myocardial ischemia have the potential to speed diagnosis of this condition.  
The work presented here will enable rapid treatment if ischemia is detected and conservation of 
expensive medical resources if it is ruled out.  
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